0001493152-21-027645.txt : 20211109 0001493152-21-027645.hdr.sgml : 20211109 20211109153836 ACCESSION NUMBER: 0001493152-21-027645 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eWELLNESS HEALTHCARE Corp CENTRAL INDEX KEY: 0001550020 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 451560906 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55203 FILM NUMBER: 211391815 BUSINESS ADDRESS: STREET 1: 1126 S FEDERAL HIGHWAY, SUITE 464 CITY: FT LAUDERDALE STATE: FL ZIP: 33316 BUSINESS PHONE: 855-470-1700 MAIL ADDRESS: STREET 1: 1126 S FEDERAL HIGHWAY, SUITE 464 CITY: FT LAUDERDALE STATE: FL ZIP: 33316 FORMER COMPANY: FORMER CONFORMED NAME: Dignyte, Inc. DATE OF NAME CHANGE: 20120515 10-Q 1 form10-q.htm
0001550020 false Q3 --12-31 0001550020 2021-01-01 2021-09-30 0001550020 2021-11-09 0001550020 2021-09-30 0001550020 2020-12-31 0001550020 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesCPreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesDPreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesDPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesEPreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesEPreferredStockMember 2020-12-31 0001550020 2021-07-01 2021-09-30 0001550020 2020-07-01 2020-09-30 0001550020 2020-01-01 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-06-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-06-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-06-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-06-30 0001550020 us-gaap:CommonStockMember 2021-06-30 0001550020 EWLL:SubscriptionReceivableMember 2021-06-30 0001550020 EWLL:SharesToBeIssuedMember 2021-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001550020 us-gaap:RetainedEarningsMember 2021-06-30 0001550020 2021-06-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-07-01 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-07-01 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-07-01 2021-09-30 0001550020 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001550020 EWLL:SubscriptionReceivableMember 2021-07-01 2021-09-30 0001550020 EWLL:SharesToBeIssuedMember 2021-07-01 2021-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001550020 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-09-30 0001550020 us-gaap:CommonStockMember 2021-09-30 0001550020 EWLL:SubscriptionReceivableMember 2021-09-30 0001550020 EWLL:SharesToBeIssuedMember 2021-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001550020 us-gaap:RetainedEarningsMember 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-06-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-06-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-06-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-06-30 0001550020 us-gaap:CommonStockMember 2020-06-30 0001550020 EWLL:SubscriptionReceivableMember 2020-06-30 0001550020 EWLL:SharesToBeIssuedMember 2020-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001550020 us-gaap:RetainedEarningsMember 2020-06-30 0001550020 2020-06-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-07-01 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-07-01 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-07-01 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-07-01 2020-09-30 0001550020 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001550020 EWLL:SubscriptionReceivableMember 2020-07-01 2020-09-30 0001550020 EWLL:SharesToBeIssuedMember 2020-07-01 2020-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001550020 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-09-30 0001550020 us-gaap:CommonStockMember 2020-09-30 0001550020 EWLL:SubscriptionReceivableMember 2020-09-30 0001550020 EWLL:SharesToBeIssuedMember 2020-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001550020 us-gaap:RetainedEarningsMember 2020-09-30 0001550020 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-12-31 0001550020 us-gaap:CommonStockMember 2020-12-31 0001550020 EWLL:SubscriptionReceivableMember 2020-12-31 0001550020 EWLL:SharesToBeIssuedMember 2020-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001550020 us-gaap:RetainedEarningsMember 2020-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-09-30 0001550020 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001550020 EWLL:SubscriptionReceivableMember 2021-01-01 2021-09-30 0001550020 EWLL:SharesToBeIssuedMember 2021-01-01 2021-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001550020 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2019-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2019-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2019-12-31 0001550020 us-gaap:CommonStockMember 2019-12-31 0001550020 EWLL:SubscriptionReceivableMember 2019-12-31 0001550020 EWLL:SharesToBeIssuedMember 2019-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001550020 us-gaap:RetainedEarningsMember 2019-12-31 0001550020 2019-12-31 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-01-01 2020-09-30 0001550020 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-09-30 0001550020 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001550020 EWLL:SubscriptionReceivableMember 2020-01-01 2020-09-30 0001550020 EWLL:SharesToBeIssuedMember 2020-01-01 2020-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001550020 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001550020 EWLL:ServicesAgreementMember EWLL:BistromaticsIncMember 2020-09-15 0001550020 EWLL:ServicesAgreementMember EWLL:BistromaticsIncMember 2020-09-14 2020-09-15 0001550020 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001550020 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001550020 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001550020 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001550020 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001550020 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001550020 EWLL:OfficersAndDirectorsMember 2021-09-30 0001550020 EWLL:OfficersAndDirectorsMember 2020-12-31 0001550020 us-gaap:ConvertibleNotesPayableMember 2021-09-30 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-01 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-12-31 0001550020 EWLL:TwoThousandNineteenConvertibleNotesMember 2020-12-31 0001550020 EWLL:OfficersDirectorsAndConsultantsMember 2019-12-31 0001550020 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesCPreferredStockMember 2021-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesDPreferredStockMember 2020-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesDPreferredStockMember 2021-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesEPreferredStockMember 2020-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesEPreferredStockMember 2021-04-30 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-05-03 2021-05-04 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-05-04 0001550020 EWLL:SeriesDVotingPreferredStockMember 2021-05-12 0001550020 EWLL:SeriesCConvertiblePreferredStockMember 2021-05-20 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-07-01 0001550020 us-gaap:CommonStockMember EWLL:BoardOfDirectorsMember 2020-02-10 2020-02-12 0001550020 us-gaap:CommonStockMember EWLL:BoardOfDirectorsMember 2019-01-01 2019-12-31 0001550020 us-gaap:CommonStockMember 2020-02-14 0001550020 EWLL:ConsultantMember 2021-01-01 2021-09-30 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-01-01 2021-09-30 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember EWLL:MonthlyMember 2020-01-01 2020-01-31 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-01-31 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2021-01-01 2021-09-30 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-09-30 0001550020 EWLL:ConvertibleNotesMember 2020-01-01 2020-09-30 0001550020 EWLL:ConvertibleNotesMember 2020-09-30 0001550020 EWLL:ConsultantMember 2020-01-01 2020-09-30 0001550020 EWLL:DerivativeLiabilityMember 2021-01-01 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember 2020-01-01 2020-09-30 0001550020 EWLL:NotesMember 2020-12-31 0001550020 EWLL:NotesMember 2021-01-01 2021-09-30 0001550020 EWLL:NotesMember 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-09-30 0001550020 us-gaap:SubsequentEventMember EWLL:SeriesEConvertiblePreferredStockMember 2021-10-01 2021-10-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure EWLL:Trading

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 000-55203

 

 

 

eWELLNESS HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada   90-1073143

(State or other jurisdiction

of incorporation or organization)

  

(I.R.S. Employer

Identification No.)

     
1126 S Federal Hwy #464, Fort Lauderdale, FL   33316
(Address of principal executive offices)   (Zip Code)

 

(855) 470-1700

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common shares   EWLL   OTC

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Ruble 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐ No ☒

 

Emerging growth company ☐

 

The number of shares of Common Stock, $0.001 per share par value, outstanding on November 9, 2021 was 18,507,683,628.

 

 

 

 

 

 

Table of Contents

 

    Page
PART I - FINANCIAL INFORMATION  3
Item 1 Financial Statements  3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations  14
Item 3 Quantitative and Qualitative Disclosures About Market Risk  17
Item 4 Controls and Procedures  17
PART II - OTHER INFORMATION  17
Item 1 Unregistered Sales of Equity Securities and Use of Proceeds  17
Item 2 Exhibits  18
Signatures    19

 

2

 

 

PART I – FINANCIAL STATEMENTS

 

ITEM 1. FINANCIAL STATEMENTS

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED CONDENSED BALANCE SHEETS

(unaudited)

   September 30, 2021   December 31, 2020 
         
ASSETS        
         
CURRENT ASSETS          
Cash  $1,620   $1,109 
Prepaid expenses   -    3,235 
           
Total current assets   1,620    4,344 
           
Property & equipment, net   2,720    3,788 
           
TOTAL ASSETS  $4,340   $8,132 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES          
Accounts payable and accrued expenses  $1,171,669   $892,164 
Accrued expenses - related party   134,247    292,762 
Accrued compensation   200,000    200,000 
Convertible debt, net of discount   1,354,882    1,354,882 
Derivative liability   3,195,452    3,925,106 
           
Total current liabilities   6,056,250    6,664,914 
           
Total Liabilities   6,056,250    6,664,914 
           
COMMITMENTS AND CONTINGENCIES   -    - 
           
STOCKHOLDERS’ DEFICIT          
Preferred stock Series A , authorized, 20,000,000 shares, $.001 par value, 696,667 and 696,667 shares issued and outstanding, respectively   697    697 
Preferred stock Series C , authorized, 1,000,000 shares, $.0001 par value, 920,000 and 0 shares issued and outstanding, respectively   92    - 
Preferred stock Series D , authorized, 200,000 shares, $.0001 par value, 200,000 and 0 shares issued and outstanding, respectively   20    - 
Preferred stock Series E Convertible , authorized, 2,500,000 shares, $.0001 par value, par value, 1,545,680 and 0 shares issued and outstanding, respectively   155    - 
Common stock, authorized 20,000,000,000 shares, $.001 par value, 17,707,683,627 and 16,862,481,961  issued and outstanding, respectively   17,707,684    16,862,482 
Subscription receivable   (68,338)   - 
Shares to be issued   -    263 
Additional paid in capital   18,003,412    16,097,866 
Accumulated deficit   (41,695,632)   (39,618,090)
           
Total Stockholders’ Deficit   (6,051,910)   (6,656,782)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $4,340   $8,132 

 

The accompanying notes are an integral part of these consolidated condensed financial statements

 

3

 

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

For the Three and Nine Months ended September 30, 2021 and 2020

(unaudited)

 

   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
   Three Months Ended   Nine Months Ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
                 
REVENUE  $-   $125,274   $-   $263,429 
                     
OPERATING EXPENSES                    
Executive compensation   -    102,000    260,000    476,000 
General and administrative   36,434    54,465    247,288    489,708 
Professional fees   1,325,551    94,867    2,106,355    945,448 
                     
Total Operating Expenses   1,361,985    251,332    2,613,643    1,911,156 
                     
Loss from Operations   (1,361,985)   (126,058)   (2,613,643)   (1,647,727)
                     
OTHER INCOME (EXPENSE)                    
Interest income   -    -    -    1 
Gain (loss) on derivative liability   (1,761,669)   1,465,693    729,654    (2,734,266)
Loss on disposal of asset   -    -    -    (3,866)
Interest expense   (65,115)   (112,837)   (193,553)   (876,870)
                     
Net Income (Loss) before Income Taxes   (3,188,769)   1,226,798    (2,077,542)   (5,262,728)
                     
Income tax expense   -    -    -    - 
                     
Net Income (Loss)  $(3,188,769)  $1,226,798   $(2,077,542)  $(5,262,728)
                     
Basic and diluted (loss) per common share  $(0.00)  $0.00   $(0.00)  $(0.00)
                     
Weighted average shares outstanding   17,707,683,627    9,749,989,477    17,279,563,597    5,049,047,707 
                     
Weighted average diluted shares outstanding   25,991,582,032    32,382,204,327    25,563,462,002    27,681,262,557 

 

The accompanying notes are an integral part of these consolidated condensed financial statements

 

4

 

 

eWELLNESS HEALTHCARE CORPORATION

RECONCILIATION OF STOCKHOLDERS’ DEFICIT

(unaudited)

 

THREE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Receivable   Issued   Capital   Deficit   Deficit 
   Preferred Shares - Series A   Preferred Shares - Series C   Preferred Shares - Series D   Preferred Shares - Series E   Common Shares   Subscription   Shares to be   Additional Paid in   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Receivable   Issued   Capital   Deficit   Deficit 
                                                             
                                                             
Balance at June 30 2021   696,667   $697    920,000   $92    200,000   $20    265,680   $27    17,707,683,627   $17,707,684   $(94,975)  $-   $16,723,540   $(38,506,864)  $(4,169,779)
                                                                            
Shares issued to officers, directors and consultants   -    -    -    -    -    -    1,280,000    128    -    -    -    -    1,279,872    -    1,280,000 
                                                                            
Shares issued for cash   -    -    -    -         -    -    -    -    -    26,637    -    -    -    26,637 
                                                                            
Shares issued for preferred share conversions   -    -    -    -         -    -    -    -    -    -    -    -    -    - 
                                                                            
Shares issued for services   -    -    -    -    -    -    -    -    -    -    -    -    -         - 
                                                                            
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    -    (3,188,769)   (3,188,769)
                                                                            
Balance at September 30, 2021   696,667   $697    920,000   $92    200,000   $20    1,545,680   $155    17,707,683,627   $17,707,684   $(68,338)  $-   $18,003,412   $(41,695,632)  $(6,051,910)
                                                                            
Balance at June 30, 2020   476,667    477    -    -    -    -    -    -    7,851,724,496    7,851,725    -    76    21,409,876    (37,351,545)   (8,089,391)
                                                                            
Contributed services   -    -    -    -    -    -    -    -    -    -    -    -    54,000    -    54,000 
                                                                            
Shares issued to officers, directors and consultants   55,000    55    -    -    -    -    -    -    -    -    -    -    164,945    -    165,000 
                                                                            
Shares issued for debt conversion   -    -    -    -    -    -    -    -    5,923,625,166    5,923,625    -    -    (5,479,659)   -    443,966 
                                                                            
Shares issued for services   -    -    -    -    -    -    -    -    -    -    -    102    -    -    102 
                                                                            
Derivative liability   -    -    -    -    -    -    -    -    -    -    -    -    1,146,368    -    1,146,368 
                                                                            
Net loss                                                                    1,226,798    1,226,798 
                                                                            
Balance at September 30, 2020   531,667   $532    -   $-    -   $-    -   $-    13,775,349,662   $13,775,350   $-   $178   $17,295,530   $(36,124,747)  $(5,053,157)

 

NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

 

   Preferred Shares - Series A   Preferred Shares - Series C   Preferred Shares - Series D   Preferred Shares - Series E   Common Shares   Subscription   Shares to be   Additional Paid in   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Receivable   Issued   Capital   Deficit   Deficit 
                                                             
Balance at December 31, 2020   696,667   $697    -   $-    -   $-    -   $-    16,862,481,961   $16,862,482   $-   $263   $16,097,866   $(39,618,090)  $(6,656,782)
                                                                            
Shares issued to officers, directors and consultants   -    -    920,000    92    200,000    20    1,280,000    128    -    -    -    -    2,399,760    -    2,400,000 
                                                                            
Shares issued for cash   -    -    -    -    -    -    350,000    35    -    -    (68,338)   -    349,965    -    281,662 
                                                                            
Shares issued for preferred share conversions   -    -    -    -    -    -    (84,320)   (8)   843,200,000    843,200    -    -    (843,192)   -    - 
                                                                            
Shares issued for services   -    -    -    -    -    -    -    -    2,001,666    2,002    -    (263)   (987)   -    752 
                                                                            
Net profit   -    -    -    -    -    -    -    -    -    -    -    -    -    (2,077,542)   (2,077,542)
                                                                            
Balance at September 30, 2021   696,667   $697    920,000   $92    200,000   $20    1,545,680   $155    17,707,683,627   $17,707,684   $(68,338)  $-   $18,003,412   $(41,695,632)  $(6,051,910)
                                                                            
Balance at December 31, 2019   250,000   $250    -   $-    -   $-    -   $-    12,752,084   $12,752   $-   $150   $23,942,830   $(30,862,019)   (6,906,037)
                                                                            
Contributed services   -    -    -    -    -    -    -    -    -    -    -    -    162,000    -    162,000 
                                                                            
Shares issued to officers, directors and consultants   281,667    282    -    -    -    -    -    -    -    -    -    -    844,718    -    845,000 
                                                                            
Shares issued for debt conversion   -    -    -    -    -    -    -    -    13,761,881,370    13,761,882    -    -    (12,161,555)   -    1,600,327 
                                                                            
Shares issued for services   -    -    -    -    -    -    -    -    668,332    668    -    28    957    -    1,653 
                                                                            
Shares issued for rounding - 50:1 split   -    -    -    -    -    -    -    -    47,876    48              (48)   -    - 
                                                                            
Derivative liability   -    -    -    -    -    -    -    -    -    -    -    -    4,506,628    -    4,506,628 
                                                                            
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    -    (5,262,728)   (5,262,728)
                                                                            
Balance at September 30, 2020   531,667   $532    -   $-    -   $-    -   $-    13,775,349,662   $13,775,350   $-   $178   $17,295,530   $(36,124,747)  $(5,053,157)

 

The accompanying notes are an integral part of these consolidated condensed financial statements

 

5

 

 

eWELLNESS HEALTHCARE CORPORATION

CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS

(unaudited)

 

   September 30, 2021   September 30, 2020 
   For Nine Months Ended 
   September 30, 2021   September 30, 2020 
         
Cash flows from operating activities          
Net income (loss)  $(2,077,542)  $(5,262,728)
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Depreciation and amortization   1,069    5,272 
Contributed services   -    162,000 
Shares issued to officers, directors and consultants   1,120,000    376,750 
Shares issued for consulting services   1,280,752    1,653 
Shares issued for financing costs   -    95,933 
Amortization of debt discount and prepaids   -    771,793 
(Gain) loss on derivative liability   (729,654)   2,734,266 
Loss on disposal of asset   -    3,866 
Changes in operating assets and liabilities          
Prepaid expense   3,235    (19,707)
Accounts receivable   -    (192,495)
Accounts payable and accrued expenses   279,504    638,533 
Accounts payable - related party   -    196,460 
Accrued expenses - related party   (158,515)   25,489 
Accrued compensation   -    182,887 
           
Net cash used in operating activities   (281,151)   (280,028)
           
Cash flows from financing activities          
Proceeds from issuance of convertible debt   -    52,800 
Original issue discount and debt issuance costs   -    (7,800)
Proceeds from issuance of preferred series E   281,662    - 
           
Net cash provided by financing activities   281,662    45,000 
           
Net increase (decrease) in cash   511    (235,028)
           
Cash, beginning of period   1,109    240,722 
           
Cash, end of period  $1,620   $5,694 
           
Supplemental Information:          
Cash paid for:          
Taxes  $-   $- 
Interest Expense  $-   $- 
Non cash items:          
Shares issued for debt conversion  $-   $1,600,327 

 

The accompanying notes are an integral part of these consolidated condensed financial statements

 

6

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

Note 1. The Company

 

The Company and Nature of Business

 

eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated minimal revenues to date.

 

eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15% ownership in Bistromatics. This agreement eliminated all past due professional fees of $748,832. The transfer of rights was completed on December 31, 2020.

 

During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company has engaged in negotiations with a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”), for a potential business combination. In connection with such negotiations, the Company’s Board of Directors on March 8, 2021, approved the organization of EWLL Acquisition Corp. under the laws of Nevada as a new wholly owned subsidiary of the Company (“EWLL Acquisition”). The purpose of the formation of EWLL Acquisition was in contemplation of its merger with and into AMHP which would be the surviving entity and become a wholly owned subsidiary of the Company.

 

Pursuant to the Company’s intentions referenced above, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition and AMHP pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company, subject to filing of Articles of Merger with the State of Nevada. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist.

 

On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. Following the filing of this Form 10Q, the application to FINRA will be filed for approval of these actions.

 

7

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 

Going Concern

 

For the nine months ended September 30, 2021, the Company had no revenue. The Company has an accumulated loss of $41,695,632 and a working capital deficit of $6,054,630. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Fair Value of Financial Instruments

 

As of September 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,195,452   $-   $-   $3,195,452 
Total Liabilities measured at fair value  $3,195,452   $-   $-   $3,195,452 

 

8

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,925,106   $-   $-   $3,925,106 
Total Liabilities measured at fair value  $3,925,106   $-   $-   $3,925,106 

 

Revenue Recognition

 

The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed.

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 

Note 3. Related Party Transactions

 

Throughout the nine months ended September 30, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of September 30, 2021 and December 31, 2020 were $34,247 and $11,655, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $221,107 and $216,107 as of September 30, 2021 and December 31, 2020, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $200,000 and $200,000 as of September 30, 2021 and December 31, 2020, respectively.

 

Note 4. Convertible Notes Payable

 

During the nine months ended September 30, 2021, there were no new convertible notes executed. During the nine months ended September 30, 2021, the Company accrued interest payable of $193,552 on previously executed convertible notes payable.

 

Year Ended December 31, 2020

 

In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. As of December 31, 2020, this note was fully converted and during the year ended December 31, 2020 the Company accrued interest of $2,880.

 

During the year ended December 31, 2020, the Company accrued interest of $330,871 for the 2019 convertible notes that were still outstanding throughout the year.

 

 

9

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

Note 5. Equity Transactions

 

Preferred Stock

 

The total number of shares of Series A Preferred Stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the year ended December 31, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $3,000,000 and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two independent directors resigned and three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. As part of the Settlement and Compromise agreements signed by current officers, director and consultant on February 26, 2021, with effective date October 1, 2020, the shares issued became fully vested at the year ended December 31, 2020.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock. The Board authorized that the Company shall have the authority to issue 1,000,000 shares with a par value of $.0001 per share to be issued to persons designated by the Board. The Series C Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series C Preferred Stock.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights Limitations of Series D Preferred Stock. The Board authorized that the Company shall have the authority to issue 200,000 shares with a par value of $.0001 per share to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock. The Board authorized that the Company shall have authority to issue 2,500,000 shares with a par value of $.0001 per share. The Board of Directors may determine to : (i) issue a number of Series Preferred in a private placement at an offering price of $1.00 per share; (ii) issue the Series E Preferred in consideration for the cancellation of shares of the Company’s Series A Preferred held by the Corporation’s officers, directors and key personnel based on terms and conditions that the Board of Directors may determine; and (iii) issue the shares of Series E Preferred for such other purposes as the Board of Directors may determine.

 

The Series C, Series D and Series E Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.

 

10

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

On May 4, 2021, the Board of Directors issued 350,000 shares of Series E Convertible Preferred Stock for the subscription agreements dated March 1, 2021 at the value of $1.00 per share. Since the full payment of $350,000 had not been received at the period ended September 30, 2021, there is a subscription receivable for $68,338.

 

On May 12, 2021, the Board of Directors authorized the issuance of 200,000 shares of Series D Voting Preferred Stock with a value of $200,000.

 

On May 20, 2021, the Board of Directors authorized the issuance of 920,000 shares of Series C Convertible Preferred Stock with a value of $920,000.

 

On July 1, 2021, the Board of Directors authorized the issuance of 1,280,000 shares of Series E Convertible Preferred Stock with a value of $1,280,000. These shares were issued on July 14, 2021.

 

Common Stock

 

On February 12, 2020, FINRA approved a 1:50 reverse split of the Company’s common stock. As noted throughout this document, all common shares are stated as if the 1:50 reverse split had been completed as of the beginning of the year ended December 31, 2020. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued 47,876 additional shares of common stock.

 

On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (1,900,000,000) shares of Common Stock to twenty billion (20,000,000,000) shares of Common Stock.

 

Nine Months Ended September 30, 2021

 

During the nine months ended September 30, 2021, the Company issued 2,001,666 shares of common stock for consultant services valued at $752.

 

During the nine months ended September 30, 2021, the Company issued 843,200,000 shares of common stock for conversion of 84,320 shares of preferred series E shares.

 

Nine Months Ended September 30, 2020

 

In January 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 shares of common stock monthly. The Company issued 80,000 shares of common stock with a value of $126. The Company needs to issue an additional 100,000 shares of common stock with a value of $20. In addition, the Company is to also pay the advisor a monthly fee of $2,500.

 

During the nine months ended September 30, 2020, the Company issued a total of 13,761,881,370 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $1,371,723 of principal, $132,671 of accrued interest and $95,933 of financing costs.

 

During the nine months ended September 30, 2020, the Company issued 668,332 shares of common stock for consultant services valued at $1,653 which includes the advisory services agreement discussed above.

 

11

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

Stock Options

 

The following is a summary of the status of all Company’s stock options as of September 30, 2021 and changes during the nine months ended on that date:

 

       Weighted         
   Number
of Stock		   Average
Exercise		   Remaining   Intrinsic 
   Options   Price   Life (yrs)   Value 
Outstanding on December 31, 2020   27,000   $40.00    .14   $- 
Granted   -    -           
Exercised   -    -           
Cancelled   (27,000)   -           
Outstanding on September 30, 2021   -    -    -   $- 
Options exercisable on September 30, 2021   -   $-    -   $- 

 

Warrants

 

The following is a summary of the status of the Company’s warrants as of September 30, 2021 and changes during the nine months ended on that date:

 

       Weighted         
   Number of   Average
Exercise		   Remaining   Intrinsic 
   Warrants   Price   Life (yrs.)   Value 
Outstanding on December 31, 2020   26,015   $12.50    1.2   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (26,015)   -    -    - 
Outstanding on September 30, 2021   -   $-    -   $- 
Warrants exercisable on September 30, 2021   -   $-    -   $- 

 

Note 6. Commitments, Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

 

Note 7. Derivative Valuation

 

The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. Therefore, these have been characterized as derivative instruments. The Company records the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. The Company records the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.

 

12

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

The debt discount is amortized over the life of the note and recognized as interest expense. For the nine months ended September 30, 2021 and 2020, the Company amortized the debt discount of $0 and $594,705, respectively.

 

During the nine months ended September 30, 2021, the Company had the following activity in the derivative liability account:

 

   Notes 
Derivative liability at December 31, 2020  $3,925,106 
Change in fair value   (729,654)
Derivative liability at September 30, 2021  $3,195,452 

 

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date  $.0005 
Risk free interest rate   .07%
Stock volatility factor   409.80%
Years to Maturity   .08 
Expected dividend yield   None 

 

Note 8. Subsequent Events

 

From October 1 until the filing of this report, the Company issued 800,000,000 shares of common stock for conversion of Series E Convertible Preferred shares.

 

13

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report include forward-looking statements. These forward-looking statements are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “proposed,” “intended,” or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. Many factors could cause our actual results to differ materially from those projected in these forward-looking statements including, but not limited to, variability of our future revenues and financial performance; risks associated with product development and technological changes; the acceptance of our products in the marketplace by potential future customers; general economic conditions. You should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.

 

The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in the financial statements of eWellness Healthcare Corporation for the nine months ended September 30, 2021 and 2020 and should be read in conjunction with such financial statements and related notes included in this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

 

THE COMPANY

 

Overview

 

The Company believes that it was the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. Our business model was to have large-scale employers use our PHZIO platform as a fully PT monitored corporate musculoskeletal treatment (“MSK”) wellness program. The Company’s PHZIO home physical therapy assessment and exercise platform was designed to achieve a market presence in the $30 billion physical therapy market, the $4 billion MSK market and the $8 billion corporate wellness industry. PHZIO is the first real-time remote monitored 1-to-many MSK physical therapy platforms for home use.

 

On May 22, 2020, the Company received and accepted the resignations of Brandon Rowberry and Rochelle Pleskow as independent directors. Their letters of resignation dated May 22, 2020, state that the reason for their resignations were to permit them to pursue other business opportunities and further stated that they have had no disagreements with the operations, policies or practices of the Company. Also, on May 22, 2020, the Company received a letter of resignation from Darwin Fogt, resigning as CEO, President and director of the Registrant and a separate letter of resignation from Curtis Hollister, resigning as CTO and director of the Company. Messrs. Fogt and Hollister are executive officers and principals of Bistromatics Inc., organized under the laws of Canada (“Bistromatics”).

 

On November 12, 2016, the Company entered into a Services Agreement with Bistromatics (the “Bistromatics Agreement”) pursuant to which Bistromatics agreed to provide operational services to the Company for its PHZIO System including development, content editing and training, support and maintenance, billing, hosting and oversight, among other services. Reference is made to the Registrant’s Form 8-K filed on November 21, 2016, which Form 8-K was signed by Darwin Fogt as CEO on behalf of the Registrant, regarding the disclosure of the Bistromatics Agreement. The Services Agreement included a provision granting Bistromatics the right to appoint 40% of the Registrant’s Board of Directors, resulting in the appointment of Messrs. Fogt and Hollister as members of the Company’s Board. Although both Companies continue to abide by the Services Agreement the Company is in arrears in fees to Bistromatics . The Service Agreement expired during the first quarter of 2020 and the parties signed a new agreement on September 15, 2020 which is discussed below.

 

14

 

 

Pursuant to communications between the Company and Darwin Fogt and Curtis Hollister regarding their resignations as executive officers and directors of the Registrant, which resignations were accepted by the Company’s Board on June 1, 2020, Messrs. Fogt and Hollister represented to the Company that Bistromatics and its management will continue to provide support services to the Company’s PHZIO System, In addition, both Darwin Fogt and Curtis Hollister confirmed that they have had no disagreements with the operations, policies or practices of the Company.

 

In connection with the resignation of Darwin Fogt as CEO, the Registrant’s Board of Directors has appointed Douglas MacLellan, who has served as the Company’s Chairman since May 2013, as Chief Executive Officer in addition to continuing to serve as the Chairman of the Board of Directors.

 

Plan of Operations

 

On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15% ownership in Bistromatics. This agreement eliminated all past due professional fees of $748,832. The transfer of rights was completed on December 31, 2020.

 

During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and Management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company has engaged in negotiations with a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”), for a potential business combination. In connection with such negotiations, the Company’s Board of Directors on March 8, 2021, approved the organization of EWLL Acquisition Corp. under the laws of Nevada as a new wholly owned subsidiary of the Company (“EWLL Acquisition”). The purpose of the formation of EWLL Acquisition was in contemplation of its merger with and into AMHP which would be the surviving entity and become a wholly owned subsidiary of the Company.

 

On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. Following the filing of this Form 10Q, the Company will file the FINRA application for approval of these actions.

 

Pursuant to the Company’s intentions referenced above, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition and AMHP pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company, subject to filing of Articles of Merger with the State of Nevada. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist.

 

Results of Operations of eWellness for the three and nine months ended September 30, 2021 vs. 2020

 

REVENUES: Total revenues for the nine months ended September 30, 2021 and 2020 were $0 and $263,429. respectively. Total revenues for the three months ended September 30, 2021 and 2020 were $0 and $125,274, respectively.

 

15

 

 

OPERATING EXPENSES: Total operating expenses increased to $2,613,643 for the nine months ended September 30, 2021 from $1,911,156 for the nine months ended September 30, 2020 reflecting a increase of $702,487. The increase resulted from an increase of number of preferred shares issued to consultants offset by decreases in accrued executive compensation and reduction and reduction in financing fees. Total operating expenses increased to $1,361,985 for the three months ended September 30, 2021 from $251,332 for the three months ended September 30, 2020 reflecting an increase of $1,110,653. The increase is a result of an increase in the number of shares of preferred shares issued to consultants offset by a reduction in financing fees and accrued executive compensation.

 

NET INCOME (LOSS): The Company had a net loss of $2,077,542 for the nine months ended September 30, 2021 compared with a net loss of $5,262,727 for the nine months ended September 30, 2020 which reflects a decrease of $3,185,185. The decrease in loss is a result of a change from loss to gain of the derivative liability on convertible debt of $3,463,920, a decrease in interest expense of $683,317 offset by an increase in operating expenses of $702,487 (as outlined above). The Company had a loss of $3,188,769 for the three months ended September 30, 2021, compared with a net income of $1,226,798 for the three months ended September 30, 2020, which reflects an increase of net loss of $4,415,567. The increase is from a change from gain to loss from the derivative liability on convertible debt of $3,227,362, a decrease in interest expense of $47,723 offset by an increase in operating expenses of $1,110,653 (as outlined above).

 

Liquidity and Capital Resources

 

As of September 30, 2021, we had negative working capital of $6,054,630 compared to negative working capital of $6,660,570 as of December 31, 2020. The negative working capital decrease is because of a decrease in derivative liability offset by an increase in accounts payable and accrued expenses. Cash used in operations was $281,151 and $280,028 for the nine months ended September 30, 2021 and 2020, respectively. The increase in cash used in operations is a result of reduction in loss offset by a change from loss to gain of the derivative liability. Cash flows provided by financing activities were $281,662 and $45,000 for the nine months ended September 30, 2021 and 2020, respectively. The increase resulted from the issuance of Preferred Series E stock for cash. The cash balance as of September 30, 2021 was $1,620.

 

We do not have sufficient cash on hand to operate. Our ability to meet our obligations and continue to operate as a going concern is highly dependent on our ability to obtain additional financing. We cannot predict whether this additional financing will be in the form of equity or debt or be in another form. We may not be able to obtain the necessary additional capital on a timely basis, on acceptable terms, or at all. In any of these events, we may be unable to implement our current plans which circumstances would have a material adverse effect on our business, prospects, financial conditions and results of operations.

 

Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2021 and December 31, 2020, respectively, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities Act of 1934.

 

Contractual Obligations and Commitments

 

From time to time the Company may become a party to litigation matters involving claims against the Company. The Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

 

Critical Accounting Policies

 

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2020, for disclosures regarding the Company’s critical accounting policies and estimates, as well as any updates further disclosed in our interim financial statements as described in this Form 10-Q.

 

16

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Smaller reporting companies are not required to provide this disclosure.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of disclosure controls and procedures.

 

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Based on that evaluation, our chief executive officer and chief financial officer concluded that, as of September 30, 2021, our disclosure controls and procedures were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules, regulations and forms, and (ii) that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in the Company’s internal controls over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

ITEM 1. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

During the three months ended September 30, 2021, the Company issued 1,280,000 shares of common stock for consultant and advisory services valued at $1,280,000.

 

17

 

 

ITEM 2 EXHIBITS

 

  (a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

 

Exhibit No.   Description
3.1(a)   Articles of Amendment to the Amended and Restated Articles of Incorporation, dated February 14, 2020 filed in the Company’s 10K for the period ended December 31, 2019.
3.2   Bylaws (Incorporated by reference to Exhibit 3(b) to the Registration Statement on Form S-1 filed on May 15, 2012)
10.30   Agreement between the Company and Bistromatics, Inc. Dated September 15, 2020 transferring Intellectual Property Rights to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms in Exchange for debt forgiveness and 15% of Bistromatics, Inc. (Incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on September 24, 2020)
10.31   Agreement and Plan of Merger dated May 18, 2021 between EWLL Acquisition Corp. and American Health Protection, Inc., filed with the Company’s Form 10Q for June 30, 2021 filed on August 23, 2021.
31.1   Certification of CEO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2   Certification of CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1   Certification of CEO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2   Certification of CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

18

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

eWellness Healthcare Corporation

(Registrant)

 

By: /s/ Douglas MacLellan   Date November 9, 2021
  Douglas MacLellan    
  Chief Executive Officer    

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Douglas MacLellan   Chief Executive Officer and Chairman of the Board   November 9, 2021
Douglas MacLellan   (Principal Executive Officer)    
         
/s/ David Markowski   Chief Financial Officer and Director   November 9, 2021
David Markowski   (Principal Financial and Accounting Officer)    
         
/s/ Douglas Cole   Director   November 9, 2021
Douglas Cole        

 

19

 

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

Exhibit 31.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Douglas MacLellan, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 of eWellness Healthcare Corporation (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made considering the circumstances made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2021  
   
/s/ Douglas MacLellan  
Douglas MacLellan  

Chief Executive Officer and Chairman of the Board

(Principal Executive Officer)

  

 

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

Exhibit 31.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, David Markowski, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 of eWellness Healthcare Corporation (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the Audit Committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9, 2021  
   
/s/ David Markowski  
David Markowski,  
Chief Financial Officer  
(Principal Financial and Accounting Officer)  

 

 

 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

Exhibit 32.1 Certification of the Chief Executive Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended September 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), the undersigned Douglas MacLellan, Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  eWellness Healthcare Corporation.
     
Date: November 9, 2021 By: /s/ Douglas MacLellan
   

Douglas MacLellan, Chief Executive Officer and

Chairman of the Board

    (Principal Executive Officer)

 

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 

 

 EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

Exhibit 32.2 Certification of the Chief Financial Officer of eWellness Healthcare Corporation pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of eWellness Healthcare Corporation (the “Company”) for the quarterly period ended September 30, 2021 as filed with the Securities and Exchange Commission (the “Report”), the undersigned David Markowski, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  eWellness Healthcare Corporation
   
Date: November 9, 2021 /s/ David Markowski
  David Markowski, Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 

 

 GRAPHIC 6 form10-q_001.jpg begin 644 form10-q_001.jpg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end EX-101.SCH 7 ewll-20210930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Condensed Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments, Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Derivative Valuation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Derivative Valuation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Derivative Valuation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ewll-20210930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 ewll-20210930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 ewll-20210930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Subscription Receivable [Member] Shares to be Issued [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Services Agreement [Member] Series [Axis] Bistromatics Inc. [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Title of Individual [Axis] Officers and Directors [Member] Debt Instrument [Axis] Convertible Notes Payable [Member] 12% Convertible Promissory Note [Member] 2019 Convertible Notes [Member] Officers,Directors and Consultants [Member] Board of Directors [Member] Series E Convertible Preferred Stock [Member] Series D Voting Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Consultant [Member] 12- month Advisory Services Agreement [Member] Scenario [Axis] Monthly [Member] Convertible Notes [Member] Award Type [Axis] Derivative Liability [Member] Derivative Instrument [Axis] Notes [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Prepaid expenses Total current assets Property & equipment, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses Accrued expenses - related party Accrued compensation Convertible debt, net of discount Derivative liability Total current liabilities Total Liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ DEFICIT Preferred stock value Common stock, authorized 20,000,000,000 shares, $.001 par value, 17,707,683,627 and 16,862,481,961  issued and outstanding, respectively Subscription receivable Shares to be issued Additional paid in capital Accumulated deficit Total Stockholders’ Deficit TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUE OPERATING EXPENSES Executive compensation General and administrative Professional fees Total Operating Expenses Loss from Operations OTHER INCOME (EXPENSE) Interest income Gain (loss) on derivative liability Loss on disposal of asset Interest expense Net Income (Loss) before Income Taxes Income tax expense Net Income (Loss) Basic and diluted (loss) per common share Weighted average shares outstanding Weighted average diluted shares outstanding Beginning balance, value Balance, shares Contributed services Shares issued to officers, directors and consultants Shares issued to officers, directors and consultants, shares Shares issued for debt conversion Shares issued for debt conversion, shares Shares issued for cash Shares issued for cash, shares Shares issued for preferred share conversions Shares issued for preferred share conversions, shares Shares issued for services Shares issued for services, shares Derivative liability Shares issued for rounding - 50:1 split Shares issued for rounding - 50:1 split, shares Net profit (loss) Ending balance, value Balance, shares Statement of Stockholders' Equity [Abstract] Stock split, description Statement of Cash Flows [Abstract] Cash flows from operating activities Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization Contributed services Shares issued to officers, directors and consultants Shares issued for consulting services Shares issued for financing costs Amortization of debt discount and prepaids (Gain) loss on derivative liability Loss on disposal of asset Changes in operating assets and liabilities Prepaid expense Accounts receivable Accounts payable and accrued expenses Accounts payable - related party Accrued expenses - related party Accrued compensation Net cash used in operating activities Cash flows from financing activities Proceeds from issuance of convertible debt Original issue discount and debt issuance costs Proceeds from issuance of preferred series E Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of period Cash, end of period Supplemental Information: Cash paid for: Taxes Interest Expense Non cash items: Shares issued for debt conversion Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company Accounting Policies [Abstract] Summary of Significant Accounting Policies Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Convertible Notes Payable Equity [Abstract] Equity Transactions Commitments and Contingencies Disclosure [Abstract] Commitments, Contingencies Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Valuation Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Going Concern Fair Value of Financial Instruments Revenue Recognition Reclassifications Summary of Assets and Liabilities Fair Value on Recurring Basis Summary of Stock Options Activity Summary of Warrants Activity Schedule of Derivative Liability Schedule of Assumptions Used Black Scholes Valuation of Derivative Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Equity Method Investment, Ownership Percentage Professional Fees Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Derivative Liability Total Liabilities measured at fair value Accumulated loss Working capital deficit Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Amounts due to officers Accrued directors fees Accrued executive compensation Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Accrued interest Debt interest stated rate Debt face amount Debt maturity date Original issue discount Transaction costs Convertible debt percentage Number of trading days Number of Stock Options Outstanding, Beginning Balance Weighted Average Exercise Price Outstanding, Beginning Balance Remaining Life (yrs) Outstanding, Beginning Balance Intrinsic Value Outstanding, Beginning Balance Number of Stock Options Outstanding, Granted Weighted Average Exercise Price, Granted Number of Stock Options Outstanding, Exercised Weighted Average Exercise Price, Exercised Number of Stock Options Outstanding, Cancelled Weighted Average Exercise Price, Cancelled Number of Stock Options Outstanding, Ending Balance Weighted Average Exercise Price Outstanding, Ending Balance Remaining Life (yrs) Outstanding, Ending Balance Intrinsic Value Outstanding, Ending Balance Number of Stock Options exercisable, Ending Balance Weighted Average Exercise Price Options exercisable, Ending Balance Remaining Life (yrs) Options exercisable, Ending Balance Intrinsic Value Options exercisable, Ending Balance Number of Warrants, Outstanding, Beginning Balance Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance Remaining Life (yrs.) Warrants Outstanding, Beginning Balance Intrinsic Value, Warrants Outstanding, Beginning Balance Number of Warrants, Granted Weighted Average Exercise Price, Warrants Granted Remaining Life (yrs.) Warrants Outstanding, Granted Intrinsic Value, Warrants Outstanding, Granted Number of Warrants, Exercised Remaining Life (yrs.) Warrants Outstanding, Exercised Intrinsic Value, Warrants Outstanding, Exercised Number of Warrants, Cancelled Remaining Life (yrs.) Warrants Outstanding, Cancelled Intrinsic Value, Warrants Outstanding, Cancelled Number of Warrants, Outstanding, Ending Balance Weighted Average Exercise Price, Warrants Outstanding, Ending Balance Remaining Life (yrs.) Warrants Outstanding, Ending Balance Intrinsic Value, Warrants Outstanding, Ending Balance Number of Warrants, exercisable, Ending balance Weighted Average Exercise Price Exercisable, Ending Balance Remaining Life (yrs.) Warrants Exercisable, Ending Balance Intrinsic Value, Warrants Outstanding, Exercisable Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock par value Preferred stock shares authorized Conversion of stock, description Conversion of Stock, Shares Converted Deferred compensation Offering price per share Preferred Stock, Voting Rights Number of shares issued, new issues Stock issued during the period, value Subscription receivable Shares issued date Reverse stock split, description Shares issued for services Value for services Number of shares issued, new issues Shares issued for debt conversion, shares Monthly base fee Principal amount Accrued interest Financing costs Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative liability, beginning balance Change in fair value Derivative liability, ending balance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock price at valuation date Derivative liability, fair value measurement input, percentage Derivative liability, term Amortized of debt discount Subsequent Event [Table] Subsequent Event [Line Items] Shares issued during period for services, shares Accrued liabilities related parties current. Subscription receivable. Shares to be issued. Subscription Receivable [Member]. Shares to be Issued [Member] Shares issued to officers, directors and cosultants. Shares issued for preferred share conversions Adjustments to additional paid in capital contributed services. Derivative liability. Stock issued during period value reverse stock splits. Stock issued during period shares officers and directors Shares issued for preferred share conversions of share Contributed services. Shares issued to officers directors and consultants. Shares issued for consulting services. Shares issued for financing costs. Increase decrease in accrued liabilities related parties. Cash Paid [Abstract] Shares issued for debt conversion. Services Agreement [Member] Bistromatics Inc. [Member] Going Concern [Policy Text Block] Working capital. Officers and Directors [Member] 12% Convertible Promissory Note [Member] 2019 Convertible Notes [Member] Officers,Directors and Consultants [Member] Board of Directors [Member] Series E Convertible Preferred Stock [Member] Series D Voting Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Consultant [Member] 12- month Advisory Services Agreement [Member] Monthly [Member] Convertible Notes [Member] Remaining Life (yrs), Ending. Number of Warrants, exercisable, Ending balance. Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share. Share Based Compensation Arrangement By Share Based Payment Award Non Option Grand In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price. Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price. Weighted Average Exercise Price, Exercisable Ending. Remaining Life (yrs), Beginning. Remaining Life (yrs.) Warrants Outstanding, Granted Remaining Life (yrs), Ending. Remaining Life (yrs), Exercisable Ending. Intrinsic Value, Warrants Outstanding. Intrinsic Value, Warrants Outstanding, Granted Intrinsic Value, Warrants Outstanding, Exercised Intrinsic Value, Warrants Outstanding, Cancelled Weighted Average Exercise Price, Warrants Exercisable Derivative Liability [Member] Notes [Member] Shares issued for debt conversion. Shares issued for debt conversion, shares. Shares issued for services. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Shares, Outstanding DerivativeLiability ContributedServices SharesIssuedToOfficersDirectorsAndConsultants Increase (Decrease) in Accounts Payable and Accrued Liabilities IncreaseDecreaseInAccruedLiabilitiesRelatedParties Increase (Decrease) in Employee Related Liabilities Net Cash Provided by (Used in) Operating Activities Payments of Debt Issuance Costs Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations SharesIssuedForDebtConversion Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Debt Conversion, Converted Instrument, Shares Issued Interest Payable, Current Derivative Liability [Default Label] EX-101.PRE 11 ewll-20210930_pre.xml XBRL PRESENTATION FILE XML 12 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001550020 2021-01-01 2021-09-30 0001550020 2021-11-09 0001550020 2021-09-30 0001550020 2020-12-31 0001550020 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesCPreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesDPreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesDPreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesEPreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesEPreferredStockMember 2020-12-31 0001550020 2021-07-01 2021-09-30 0001550020 2020-07-01 2020-09-30 0001550020 2020-01-01 2020-09-30 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001550020 us-gaap:CommonStockMember 2021-06-30 0001550020 EWLL:SubscriptionReceivableMember 2021-06-30 0001550020 EWLL:SharesToBeIssuedMember 2021-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001550020 us-gaap:RetainedEarningsMember 2021-06-30 0001550020 2021-06-30 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001550020 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001550020 EWLL:SubscriptionReceivableMember 2021-07-01 2021-09-30 0001550020 EWLL:SharesToBeIssuedMember 2021-07-01 2021-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001550020 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001550020 us-gaap:CommonStockMember 2021-09-30 0001550020 EWLL:SubscriptionReceivableMember 2021-09-30 0001550020 EWLL:SharesToBeIssuedMember 2021-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001550020 us-gaap:RetainedEarningsMember 2021-09-30 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0001550020 us-gaap:CommonStockMember 2020-06-30 0001550020 EWLL:SubscriptionReceivableMember 2020-06-30 0001550020 EWLL:SharesToBeIssuedMember 2020-06-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001550020 us-gaap:RetainedEarningsMember 2020-06-30 0001550020 2020-06-30 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001550020 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001550020 EWLL:SubscriptionReceivableMember 2020-07-01 2020-09-30 0001550020 EWLL:SharesToBeIssuedMember 2020-07-01 2020-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001550020 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001550020 us-gaap:CommonStockMember 2020-09-30 0001550020 EWLL:SubscriptionReceivableMember 2020-09-30 0001550020 EWLL:SharesToBeIssuedMember 2020-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001550020 us-gaap:RetainedEarningsMember 2020-09-30 0001550020 2020-09-30 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001550020 us-gaap:CommonStockMember 2020-12-31 0001550020 EWLL:SubscriptionReceivableMember 2020-12-31 0001550020 EWLL:SharesToBeIssuedMember 2020-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001550020 us-gaap:RetainedEarningsMember 2020-12-31 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001550020 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001550020 EWLL:SubscriptionReceivableMember 2021-01-01 2021-09-30 0001550020 EWLL:SharesToBeIssuedMember 2021-01-01 2021-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001550020 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001550020 us-gaap:CommonStockMember 2019-12-31 0001550020 EWLL:SubscriptionReceivableMember 2019-12-31 0001550020 EWLL:SharesToBeIssuedMember 2019-12-31 0001550020 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001550020 us-gaap:RetainedEarningsMember 2019-12-31 0001550020 2019-12-31 0001550020 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001550020 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001550020 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001550020 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-09-30 0001550020 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001550020 EWLL:SubscriptionReceivableMember 2020-01-01 2020-09-30 0001550020 EWLL:SharesToBeIssuedMember 2020-01-01 2020-09-30 0001550020 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001550020 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001550020 EWLL:ServicesAgreementMember EWLL:BistromaticsIncMember 2020-09-15 0001550020 EWLL:ServicesAgreementMember EWLL:BistromaticsIncMember 2020-09-14 2020-09-15 0001550020 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001550020 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001550020 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001550020 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001550020 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001550020 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001550020 EWLL:OfficersAndDirectorsMember 2021-09-30 0001550020 EWLL:OfficersAndDirectorsMember 2020-12-31 0001550020 us-gaap:ConvertibleNotesPayableMember 2021-09-30 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-03-01 2020-03-31 0001550020 EWLL:TwelvePercentConvertiblePromissoryNoteMember 2020-12-31 0001550020 EWLL:TwoThousandNineteenConvertibleNotesMember 2020-12-31 0001550020 EWLL:OfficersDirectorsAndConsultantsMember 2019-12-31 0001550020 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesCPreferredStockMember 2021-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesDPreferredStockMember 2020-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesDPreferredStockMember 2021-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesEPreferredStockMember 2020-04-30 0001550020 EWLL:BoardOfDirectorsMember us-gaap:SeriesEPreferredStockMember 2021-04-30 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-05-03 2021-05-04 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-05-04 0001550020 EWLL:SeriesDVotingPreferredStockMember 2021-05-12 0001550020 EWLL:SeriesCConvertiblePreferredStockMember 2021-05-20 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-07-01 0001550020 EWLL:BoardOfDirectorsMember us-gaap:CommonStockMember 2020-02-10 2020-02-12 0001550020 EWLL:BoardOfDirectorsMember us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001550020 us-gaap:CommonStockMember 2020-02-14 0001550020 EWLL:ConsultantMember 2021-01-01 2021-09-30 0001550020 EWLL:SeriesEConvertiblePreferredStockMember 2021-01-01 2021-09-30 0001550020 EWLL:MonthlyMember EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-01-31 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-01-01 2020-01-31 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2021-01-01 2021-09-30 0001550020 EWLL:TwelveMonthAdvisoryServicesAgreementMember 2020-09-30 0001550020 EWLL:ConvertibleNotesMember 2020-01-01 2020-09-30 0001550020 EWLL:ConvertibleNotesMember 2020-09-30 0001550020 EWLL:ConsultantMember 2020-01-01 2020-09-30 0001550020 EWLL:DerivativeLiabilityMember 2021-01-01 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember 2020-01-01 2020-09-30 0001550020 EWLL:NotesMember 2020-12-31 0001550020 EWLL:NotesMember 2021-01-01 2021-09-30 0001550020 EWLL:NotesMember 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-30 0001550020 EWLL:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-09-30 0001550020 EWLL:SeriesEConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2021-10-01 2021-10-02 iso4217:USD shares iso4217:USD shares pure EWLL:Trading 0001550020 false Q3 --12-31 10-Q true 2021-09-30 2021 false 000-55203 eWELLNESS HEALTHCARE CORPORATION NV 90-1073143 1126 S Federal Hwy #464 Fort Lauderdale FL 33316 (855) 470-1700 Common shares EWLL Yes Yes Non-accelerated Filer true false false 18507683628 1620 1109 3235 1620 4344 2720 3788 4340 8132 1171669 892164 134247 292762 200000 200000 1354882 1354882 3195452 3925106 6056250 6664914 6056250 6664914 20000000 20000000 0.001 0.001 696667 696667 696667 696667 697 697 1000000 1000000 0.0001 0.0001 920000 920000 0 0 92 200000 200000 0.0001 0.0001 200000 200000 0 0 20 2500000 2500000 0.0001 0.0001 1545680 1545680 0 0 155 20000000000 20000000000 0.001 0.001 17707683627 17707683627 16862481961 16862481961 17707684 16862482 -68338 263 18003412 16097866 -41695632 -39618090 -6051910 -6656782 4340 8132 125274 263429 102000 260000 476000 36434 54465 247288 489708 1325551 94867 2106355 945448 1361985 251332 2613643 1911156 -1361985 -126058 -2613643 -1647727 1 -1761669 1465693 729654 -2734266 -3866 65115 112837 193553 876870 -3188769 1226798 -2077542 -5262728 -3188769 1226798 -2077542 -5262728 -0.00 0.00 -0.00 -0.00 17707683627 9749989477 17279563597 5049047707 25991582032 32382204327 25563462002 27681262557 696667 697 920000 92 200000 20 265680 27 17707683627 17707684 -94975 16723540 -38506864 -4169779 1280000 128 1279872 1280000 26637 26637 -3188769 -3188769 696667 697 920000 92 200000 20 1545680 155 17707683627 17707684 -68338 18003412 -41695632 -6051910 476667 477 7851724496 7851725 76 21409876 -37351545 -8089391 54000 54000 55000 55 164945 165000 5923625166 5923625 -5479659 443966 102 102 1146368 1146368 1226798 1226798 531667 532 13775349662 13775350 178 17295530 -36124747 -5053157 696667 697 16862481961 16862482 263 16097866 -39618090 -6656782 920000 92 200000 20 1280000 128 2399760 2400000 350000 35 -68338 349965 281662 -84320 -8 843200000 843200 -843192 2001666 2002 -263 -987 752 -2077542 -2077542 696667 697 920000 92 200000 20 1545680 155 17707683627 17707684 -68338 18003412 -41695632 -6051910 250000 250 12752084 12752 150 23942830 -30862019 -6906037 162000 162000 281667 282 844718 845000 13761881370 13761882 -12161555 1600327 668332 668 28 957 1653 50:1 split 47876 48 -48 4506628 4506628 -5262728 -5262728 -5262728 -5262728 531667 532 13775349662 13775350 178 17295530 -36124747 -5053157 -2077542 -5262728 1069 5272 162000 1120000 376750 1280752 1653 95933 771793 729654 -2734266 -3866 3235 -19707 -192495 279504 638533 196460 -158515 25489 182887 -281151 -280028 52800 7800 281662 281662 45000 511 -235028 1109 240722 1620 5694 1600327 <p id="xdx_808_eus-gaap--NatureOfOperations_zobx6vfSXmT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 1. <span id="xdx_828_zWAJEPlsImnl">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">The Company and Nature of Business</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated minimal revenues to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200915__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__dei--LegalEntityAxis__custom--BistromaticsIncMember_z99MxTWGR3Od" title="Equity Method Investment, Ownership Percentage">15</span>% ownership in Bistromatics. This agreement eliminated all past due professional fees of $<span id="xdx_90A_eus-gaap--ProfessionalFees_pp0p0_c20200914__20200915__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember__dei--LegalEntityAxis__custom--BistromaticsIncMember_zc3jP45oBLJf" title="Professional Fees">748,832</span>. The transfer of rights was completed on December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company has engaged in negotiations with a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”), for a potential business combination. In connection with such negotiations, the Company’s Board of Directors on March 8, 2021, approved the organization of EWLL Acquisition Corp. under the laws of Nevada as a new wholly owned subsidiary of the Company (“EWLL Acquisition”). The purpose of the formation of EWLL Acquisition was in contemplation of its merger with and into AMHP which would be the surviving entity and become a wholly owned subsidiary of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the Company’s intentions referenced above, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition and AMHP pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company, subject to filing of Articles of Merger with the State of Nevada. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. Following the filing of this Form 10Q, the application to FINRA will be filed for approval of these actions.</span></p> 0.15 748832 <p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z9ag8Nwg7ui2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 2. <span id="xdx_823_zuPp8MCVt4Ea">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSbUPJFAyuU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86A_zPwT42pzjTo9">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zuIplAcQKqFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_zxvv3vCM39M4">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_zhEe8rRQKC51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_zXP6Hb7c2HLh">Going Concern</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the nine months ended September 30, 2021, the Company had no revenue. The Company has an accumulated loss of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20210930_zgC0hj83otJ5" title="Accumulated loss">41,695,632</span> and a working capital deficit of $<span id="xdx_90C_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20210930_zsLxbKVn9ez5" title="Working capital deficit">6,054,630</span>. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zmZagmCP9ull" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_869_zH2QE4xbTEM8">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zAZPI7jY0XV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B1_zxm0o2FvqU35" style="display: none">Summary of Assets and Liabilities Fair Value on Recurring Basis</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210930_zEuOc9qGNI95" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zSqFI1SJTFb2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgH64nnoh1Lc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5LAVoNbvWld" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 2.5pt">Derivative Liability</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">3,195,452</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">3,195,452</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,195,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,195,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>eWellness Healthcare Corporation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Consolidated Condensed Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200930_zGs1oaXF2GA1" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z7KM9EPKBPAe" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zImjCEBjzIl" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zTZIXvGRids7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_zMYnuFK7JuQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Derivative Liability</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">3,925,106</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">3,925,106</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zTcugRDk2HVe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,925,106</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,925,106</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zhUD3o4snEgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zKaGRY8hbP6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_867_zfUSXt6BALu4">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zcQzKbrAOGme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_861_zrYY6btHIFCb">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p id="xdx_85C_zKnnPFh4ezl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSbUPJFAyuU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86A_zPwT42pzjTo9">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zuIplAcQKqFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_zxvv3vCM39M4">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_ecustom--GoingConcernPolicyTextBlock_zhEe8rRQKC51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_zXP6Hb7c2HLh">Going Concern</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the nine months ended September 30, 2021, the Company had no revenue. The Company has an accumulated loss of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20210930_zgC0hj83otJ5" title="Accumulated loss">41,695,632</span> and a working capital deficit of $<span id="xdx_90C_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20210930_zsLxbKVn9ez5" title="Working capital deficit">6,054,630</span>. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> -41695632 6054630 <p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zmZagmCP9ull" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_869_zH2QE4xbTEM8">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zAZPI7jY0XV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B1_zxm0o2FvqU35" style="display: none">Summary of Assets and Liabilities Fair Value on Recurring Basis</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210930_zEuOc9qGNI95" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zSqFI1SJTFb2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgH64nnoh1Lc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5LAVoNbvWld" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 2.5pt">Derivative Liability</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">3,195,452</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">3,195,452</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,195,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,195,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>eWellness Healthcare Corporation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Consolidated Condensed Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200930_zGs1oaXF2GA1" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z7KM9EPKBPAe" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zImjCEBjzIl" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zTZIXvGRids7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_zMYnuFK7JuQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Derivative Liability</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">3,925,106</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">3,925,106</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zTcugRDk2HVe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,925,106</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,925,106</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zhUD3o4snEgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zAZPI7jY0XV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B1_zxm0o2FvqU35" style="display: none">Summary of Assets and Liabilities Fair Value on Recurring Basis</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210930_zEuOc9qGNI95" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zSqFI1SJTFb2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgH64nnoh1Lc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5LAVoNbvWld" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 2.5pt">Derivative Liability</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">3,195,452</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">3,195,452</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,195,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,195,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>eWellness Healthcare Corporation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Consolidated Condensed Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200930_zGs1oaXF2GA1" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z7KM9EPKBPAe" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zImjCEBjzIl" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zTZIXvGRids7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pp0p0_zMYnuFK7JuQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Derivative Liability</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">3,925,106</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">3,925,106</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_zTcugRDk2HVe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,925,106</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,925,106</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3195452 3195452 3195452 3195452 3925106 3925106 3925106 3925106 <p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zKaGRY8hbP6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_867_zfUSXt6BALu4">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zcQzKbrAOGme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_861_zrYY6btHIFCb">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zt8bGdYLO2rj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 3. <span id="xdx_82C_z29UnmlYgnq">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Throughout the nine months ended September 30, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of September 30, 2021 and December 31, 2020 were $<span id="xdx_901_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20210930__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zpqiBHCz6xD3" title="Due to Related Parties, Current">34,247</span> and $<span id="xdx_904_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20201231__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_zFeFrinpoDj4" title="Amounts due to officers">11,655</span>, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $<span id="xdx_90F_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pp0p0_c20210930_zIu3zlNBN4I3" title="Accrued Professional Fees">221,107</span> and $<span id="xdx_90C_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_pp0p0_c20201231_zHbpppuX5U7i" title="Accrued directors fees">216,107</span> as of September 30, 2021 and December 31, 2020, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $<span id="xdx_906_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_c20210930_z1tBl3QENQNb" title="Employee-related Liabilities, Current">200,000</span> and $<span id="xdx_90A_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_c20201231_zPEYrZ6BxsNd" title="Accrued executive compensation">200,000</span> as of September 30, 2021 and December 31, 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 34247 11655 221107 216107 200000 200000 <p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zHsWrtuv2h61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 4. <span id="xdx_822_zLSR8mh3iZ2k">Convertible Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, there were no new convertible notes executed. During the nine months ended September 30, 2021, the Company accrued interest payable of $<span id="xdx_906_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20210930__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zc3ZpNqyJFcf" title="Accrued interest">193,552</span> on previously executed convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Year Ended December 31, 2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In March 2020, the Company executed a <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zrWZVNwwFCL1" title="Debt interest stated rate">12</span>% Convertible Promissory Note payable to an institutional investor in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zPW2RRhDHQN2" title="Debt face amount">52,800</span>. The note, which is due on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zNJ3EDXUH1Yg" title="Debt maturity date">January 15, 2021</span>, has an original issue discount of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zUDxDymAzSZa" title="Original issue discount">4,800</span> and transaction costs of $<span id="xdx_90E_eus-gaap--DeferredFinanceCostsNet_iI_pp0p0_c20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zzlJlCHMDySi" title="Transaction costs">3,000</span>. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_uPure_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_z3FruSWGTlu2" title="Convertible debt percentage">70</span>% of the average of the two lowest per share trading prices for the ten (<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_dtD_uTradingDays_c20200301__20200331__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_zjQJo6ezGEF7" title="Number of trading days">10</span>) trading days prior to the conversion date. As of December 31, 2020, this note was fully converted and during the year ended December 31, 2020 the Company accrued interest of $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20201231__us-gaap--DebtInstrumentAxis__custom--TwelvePercentConvertiblePromissoryNoteMember_z0wLAP4b8Gt2" title="Accrued interest">2,880</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2020, the Company accrued interest of $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandNineteenConvertibleNotesMember_zV54r6BV8tD4" title="Accrued interest">330,871</span> for the 2019 convertible notes that were still outstanding throughout the year.</span></p> 193552 0.12 52800 2021-01-15 4800 3000 0.70 10 2880 330871 <p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zVZrqa2o24E9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 5. <span id="xdx_820_zgSnjM201Db1">Equity Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The total number of shares of Series A Preferred Stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4CJZ6hMVyN3" title="Preferred stock, par value">0.001</span> per share. During the year ended December 31, 2019, the Company authorized the issuance of <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20191231__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndConsultantsMember_zxQyI4TbHllh" title="Preferred stock, shares authorized">1,000,000</span> shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. <span id="xdx_909_eus-gaap--ConversionOfStockDescription_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBw3pNWsz6Vi" title="Conversion of stock, description">The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYdi37e4rmN9">40</span> shares per preferred share at the common share value on the date of issuance.</span> The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $<span id="xdx_909_eus-gaap--DeferredCompensationEquity_iI_pid_c20210930_zg8xcgnrOZ49" title="Deferred compensation">3,000,000</span> and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two independent directors resigned and three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. As part of the Settlement and Compromise agreements signed by current officers, director and consultant on February 26, 2021, with effective date October 1, 2020, the shares issued became fully vested at the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In April 2021, the Board of Directors issued a Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock. The Board authorized that the Company shall have the authority to issue <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zgHMgSIkQ0Qd" title="Preferred stock shares authorized">1,000,000</span> shares with a par value of $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zd8JVjBPH1p5" title="Preferred stock par value">.0001</span> per share to be issued to persons designated by the Board. The Series C Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series C Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights Limitations of Series D Preferred Stock. The Board authorized that the Company shall have the authority to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zbGGcEphNSX8">200,000</span> shares with a par value of $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zp5WAJXVKyb7">.0001</span> per share to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock. The Board authorized that the Company shall have authority to issue <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z0cGMY0cBZQa" title="Preferred stock shares authorized">2,500,000</span> shares with a par value of $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z8JgFhmqVlNh" title="Preferred stock par value">.0001</span> per share. The Board of Directors may determine to : (i) issue a number of Series Preferred in a private placement at an offering price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zNbgQoGTovnk" title="Offering price per share">1.00</span> per share; (ii) issue the Series E Preferred in consideration for the cancellation of shares of the Company’s Series A Preferred held by the Corporation’s officers, directors and key personnel based on terms and conditions that the Board of Directors may determine; and (iii) issue the shares of Series E Preferred for such other purposes as the Board of Directors may determine.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Series C, Series D and Series E Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others) existing subsidiaries of the Corporation. <span id="xdx_903_eus-gaap--PreferredStockVotingRights_c20210101__20210930_zjvrcibfzXdh">The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>eWellness Healthcare Corporation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Consolidated Condensed Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On May 4, 2021, the Board of Directors issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210503__20210504__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zWNElBTo2qE8">350,000</span> shares of Series E Convertible Preferred Stock for the subscription agreements dated March 1, 2021 at the value of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210504__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_z425FxSVSAAj">1.00</span> per share. Since the full payment of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210503__20210504__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zkG9xEUUidIl">350,000</span> had not been received at the period ended September 30, 2021, there is a subscription receivable for $<span id="xdx_907_ecustom--SubscriptionReceivable_iNI_di_c20210930_zF7u69FJCHI8" title="Subscription receivable">68,338</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On May 12, 2021, the Board of Directors authorized the issuance of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210512__us-gaap--StatementClassOfStockAxis__custom--SeriesDVotingPreferredStockMember_zlr7MWbXVVFd">200,000</span> shares of Series D Voting Preferred Stock with a value of $<span id="xdx_909_eus-gaap--PreferredStockValue_iI_pid_c20210512__us-gaap--StatementClassOfStockAxis__custom--SeriesDVotingPreferredStockMember_z6Jfeh35zuwj" title="Preferred stock value">200,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On May 20, 2021, the Board of Directors authorized the issuance of <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210520__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zCfrLkjiE8Nk">920,000</span> shares of Series C Convertible Preferred Stock with a value of $<span id="xdx_90D_eus-gaap--PreferredStockValue_iI_pid_c20210520__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zS6E5NMj1m45">920,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On July 1, 2021, the Board of Directors authorized the issuance of <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210701__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zQ0F07oE7Eu2">1,280,000</span> shares of Series E Convertible Preferred Stock with a value of $<span id="xdx_900_eus-gaap--PreferredStockValue_iI_pid_c20210701__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_z1g5nrUbOkF" title="Preferred stock value">1,280,000</span>. These shares were issued on <span id="xdx_90F_eus-gaap--PreferredStockConvertibleConversionDate_iI_pid_dd_c20210701__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zw1wdnhH6pF5" title="Shares issued date">July 14, 2021</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Common Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On February 12, 2020, FINRA approved a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20200210__20200212__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zHUxwV7Cga99" title="Reverse stock split, description">1:50</span> reverse split of the Company’s common stock. As noted throughout this document, all common shares are stated as if the <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zjfUBrMZzifg" title="Reverse stock split, description">1:50</span> reverse split had been completed as of the beginning of the year ended December 31, 2020. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zNPXAh0cXWj1" title="Number of shares issued, new issues">47,876</span> additional shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (<span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20200214__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeBwN253FPqe" title="Common stock, shares authorized">1,900,000,000</span>) shares of Common Stock to twenty billion (<span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNld7WLdZcuf" title="Common stock, shares authorized">20,000,000,000</span>) shares of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Nine Months Ended September 30, 2021</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210101__20210930__srt--TitleOfIndividualAxis__custom--ConsultantMember_zFboy6DRDYl5" title="Shares issued for services">2,001,666</span> shares of common stock for consultant services valued at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20210101__20210930__srt--TitleOfIndividualAxis__custom--ConsultantMember_zdcJuoSXqO9j" title="Value for services">752</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, the Company issued <span id="xdx_902_ecustom--SharesIssuedForPreferredShareConversionsOfShare_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRfDhGPLsWGf" title="Number of shares issued, new issues">843,200,000</span> shares of common stock for conversion of <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zD3hxteWb1tf" title="Shares issued for debt conversion, shares">84,320</span> shares of preferred series E shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Nine Months Ended September 30, 2020</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In January 2020, the Company executed a 12-month advisory services agreement. The Company is to issue <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember__srt--StatementScenarioAxis__custom--MonthlyMember_zjYVR1LqYj6" title="Number of shares issued, new issues">20,000</span> shares of common stock monthly. The Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_zSBYEimvr24b" title="Number of shares issued, new issues">80,000</span> shares of common stock with a value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_zT5HZeoj8iPk" title="Stock issued during the period, value">126</span>. The Company needs to issue an additional <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_z4wnvlTZjsjl">100,000</span> shares of common stock with a value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_zwdlxSv4YaAb">20</span>. In addition, the Company is to also pay the advisor a monthly fee of $<span id="xdx_905_eus-gaap--ManagementFeePayable_iI_pp0p0_c20200930__us-gaap--TypeOfArrangementAxis__custom--TwelveMonthAdvisoryServicesAgreementMember_zHLW4RrSXiL9" title="Monthly base fee">2,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2020, the Company issued a total of <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200101__20200930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zco96yRogxX2" title="Shares issued for debt conversion, shares">13,761,881,370</span> shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pip0_c20200930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zKgeX3XvByH9" title="Principal amount">1,371,723</span> of principal, $<span id="xdx_908_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20200930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zlM8pZJhUA63" title="Accrued interest">132,671</span> of accrued interest and $<span id="xdx_907_eus-gaap--PaymentsOfFinancingCosts_pp0p0_c20200101__20200930__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zyLRZEXfAJC6" title="Financing costs">95,933</span> of financing costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2020, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20200101__20200930__srt--TitleOfIndividualAxis__custom--ConsultantMember_zYyGwdaPcxJ6">668,332</span> shares of common stock for consultant services valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20200101__20200930__srt--TitleOfIndividualAxis__custom--ConsultantMember_z4mUtQaM3hbe">1,653</span> which includes the advisory services agreement discussed above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>eWellness Healthcare Corporation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Consolidated Condensed Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Stock Options</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zelkkkeN3t2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following is a summary of the status of all Company’s stock options as of September 30, 2021 and changes during the nine months ended on that date:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zKDwAo3hWwNj" style="display: none">Summary of Stock Options Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Number <br/> of Stock</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average <br/> Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (yrs)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding on December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930_zsGE50kSIq15" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance">27,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930_zph2IBpV93Hd" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning Balance">40.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_zLYqPI2k2ZK2" title="Remaining Life (yrs) Outstanding, Beginning Balance">.14</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210101__20210930_zG1rabwsgSmd" style="width: 11%; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930_zLr4fD0tNFJ9" style="text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_z3WRRtbPFfp6" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20210930_zA8ZLzyibQMg" style="text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zAZ2BCZ2F5Uk" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930_zpkxQTQ753ee" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Options Outstanding, Cancelled">(27,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zY8SAsrztmEh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding on September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930_zbqVnRietIC" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930_zKFKVUGQN6y7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20210930_zCahYOP9sw0h" title="Remaining Life (yrs) Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210101__20210930_z7i2tKCUsZt2" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable on September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210930_zTUy4rAXrtk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1076">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210930_zdSQplsBfoWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY0_c20210101__20210930_z7lUF51y2sai" title="Remaining Life (yrs) Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210930_zV7H7VhAxcD3" title="Intrinsic Value Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1082">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zDXSw28q9NC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zgjL27Ab2Tsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following is a summary of the status of the Company’s warrants as of September 30, 2021 and changes during the nine months ended on that date:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B7_zmb5WtPjZAd8" style="display: none">Summary of Warrants Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average <br/>Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (yrs.)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding on December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20210930_zsYnFSetsQNa" style="width: 11%; text-align: right" title="Number of Warrants, Outstanding, Beginning Balance">26,015</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20210101__20210930_zHWJ4D6UnJ59" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance">12.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_zmZ0yJ1psH4b" style="width: 11%; text-align: right" title="Remaining Life (yrs.) Warrants Outstanding, Beginning Balance">1.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iS_c20210101__20210930_zwtzjbNm5ws1" style="width: 11%; text-align: right" title="Intrinsic Value, Warrants Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1092">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20210930_zHKyx6Z0YGLa" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zNftXQYBvyta" style="text-align: right" title="Weighted Average Exercise Price, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTermGranted_dtY0_c20210101__20210930_zjR6WHjeIcdh" style="text-align: right" title="Remaining Life (yrs.) Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantGrantedInPeriodGrantDateIntrinsic_c20210101__20210930_zFbbeQPZxJJg" style="text-align: right" title="Intrinsic Value, Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20210930_zE0WFO9MObU4" style="text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisdInPeriodWeightedAverageExercisePrice_c20210101__20210930_zc16adolIih9" style="text-align: right" title="Weighted Average Exercise Price, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1104">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisdInPeriodWeightedAverageExercisePrice_c20210101__20210930_zRwFHJ7w12cl" style="text-align: right" title="Remaining Life (yrs.) Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisedInPeriodGrantDateIntrinsic_c20210101__20210930_zt3WxLxphrKj" style="text-align: right" title="Intrinsic Value, Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20210930_z7JFSP44CQbh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Cancelled">(26,015</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210930_zIL3BSWKLwhc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210930_zWHXJW5QKNP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Remaining Life (yrs.) Warrants Outstanding, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantCancelledInPeriodGrantDateIntrinsic_c20210101__20210930_zW4P2cuiwT77" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value, Warrants Outstanding, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding on September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20210930_zxPDBI2v3Ock" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1118">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_c20210101__20210930_zW6IsDMlPBS5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingEndingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20210930_z6Ku6nUNaSBi" title="Remaining Life (yrs.) Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iE_c20210101__20210930_zUCKl0GNF8Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants exercisable on September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber_iI_pid_c20210930_zkTIfnToXvfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, exercisable, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare_iI_c20210930_zhPrq7e4otml" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsExercisableWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20210930_zXzXzjdpRqN" title="Remaining Life (yrs.) Warrants Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisableInPeriodGrantDateIntrinsic_iI_c20210930_zCSBfH2GwIRh" title="Intrinsic Value, Warrants Outstanding, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1132">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zrASFNk4lzVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 0.001 1000000 The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. 40 3000000 1000000 0.0001 200000 0.0001 2500000 0.0001 1.00 The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time. 350000 1.00 350000 -68338 200000 200000 920000 920000 1280000 1280000 2021-07-14 1:50 1:50 47876 1900000000 20000000000 2001666 752 843200000 84320 20000 80000 126 100000 20 2500 13761881370 1371723 132671 95933 668332 1653 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zelkkkeN3t2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following is a summary of the status of all Company’s stock options as of September 30, 2021 and changes during the nine months ended on that date:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zKDwAo3hWwNj" style="display: none">Summary of Stock Options Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Number <br/> of Stock</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average <br/> Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (yrs)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding on December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930_zsGE50kSIq15" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance">27,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930_zph2IBpV93Hd" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning Balance">40.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_zLYqPI2k2ZK2" title="Remaining Life (yrs) Outstanding, Beginning Balance">.14</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210101__20210930_zG1rabwsgSmd" style="width: 11%; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930_zLr4fD0tNFJ9" style="text-align: right" title="Number of Stock Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_z3WRRtbPFfp6" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20210930_zA8ZLzyibQMg" style="text-align: right" title="Number of Stock Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zAZ2BCZ2F5Uk" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930_zpkxQTQ753ee" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Options Outstanding, Cancelled">(27,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zY8SAsrztmEh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding on September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930_zbqVnRietIC" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930_zKFKVUGQN6y7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20210930_zCahYOP9sw0h" title="Remaining Life (yrs) Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210101__20210930_z7i2tKCUsZt2" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable on September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210930_zTUy4rAXrtk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1076">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210930_zdSQplsBfoWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY0_c20210101__20210930_z7lUF51y2sai" title="Remaining Life (yrs) Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20210930_zV7H7VhAxcD3" title="Intrinsic Value Options exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1082">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 27000 40.00 P0Y1M20D 27000 <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zgjL27Ab2Tsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following is a summary of the status of the Company’s warrants as of September 30, 2021 and changes during the nine months ended on that date:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B7_zmb5WtPjZAd8" style="display: none">Summary of Warrants Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average <br/>Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (yrs.)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding on December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20210930_zsYnFSetsQNa" style="width: 11%; text-align: right" title="Number of Warrants, Outstanding, Beginning Balance">26,015</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iS_pid_c20210101__20210930_zHWJ4D6UnJ59" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance">12.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_zmZ0yJ1psH4b" style="width: 11%; text-align: right" title="Remaining Life (yrs.) Warrants Outstanding, Beginning Balance">1.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iS_c20210101__20210930_zwtzjbNm5ws1" style="width: 11%; text-align: right" title="Intrinsic Value, Warrants Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1092">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20210930_zHKyx6Z0YGLa" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zNftXQYBvyta" style="text-align: right" title="Weighted Average Exercise Price, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTermGranted_dtY0_c20210101__20210930_zjR6WHjeIcdh" style="text-align: right" title="Remaining Life (yrs.) Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantGrantedInPeriodGrantDateIntrinsic_c20210101__20210930_zFbbeQPZxJJg" style="text-align: right" title="Intrinsic Value, Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20210930_zE0WFO9MObU4" style="text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisdInPeriodWeightedAverageExercisePrice_c20210101__20210930_zc16adolIih9" style="text-align: right" title="Weighted Average Exercise Price, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1104">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisdInPeriodWeightedAverageExercisePrice_c20210101__20210930_zRwFHJ7w12cl" style="text-align: right" title="Remaining Life (yrs.) Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisedInPeriodGrantDateIntrinsic_c20210101__20210930_zt3WxLxphrKj" style="text-align: right" title="Intrinsic Value, Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20210101__20210930_z7JFSP44CQbh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Cancelled">(26,015</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210930_zIL3BSWKLwhc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210930_zWHXJW5QKNP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Remaining Life (yrs.) Warrants Outstanding, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantCancelledInPeriodGrantDateIntrinsic_c20210101__20210930_zW4P2cuiwT77" style="border-bottom: Black 1.5pt solid; text-align: right" title="Intrinsic Value, Warrants Outstanding, Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding on September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20210930_zxPDBI2v3Ock" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1118">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare_iE_c20210101__20210930_zW6IsDMlPBS5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingEndingWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20210930_z6Ku6nUNaSBi" title="Remaining Life (yrs.) Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic_iE_c20210101__20210930_zUCKl0GNF8Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Warrants Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants exercisable on September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber_iI_pid_c20210930_zkTIfnToXvfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, exercisable, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare_iI_c20210930_zhPrq7e4otml" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentWarrantsExercisableWeightedAverageRemainingContractualTerm2_dtY0_c20210101__20210930_zXzXzjdpRqN" title="Remaining Life (yrs.) Warrants Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisableInPeriodGrantDateIntrinsic_iI_c20210930_zCSBfH2GwIRh" title="Intrinsic Value, Warrants Outstanding, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1132">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 26015 12.50 P1Y2M12D 26015 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zjpc3nNw6Zg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 6. <span id="xdx_827_zcnts12V6Gc9">Commitments, Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_807_eus-gaap--DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_zgczwUiP7NJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 7. <span id="xdx_822_z7V5k9ZBJARl">Derivative Valuation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. Therefore, these have been characterized as derivative instruments. The Company records the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. The Company records the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>eWellness Healthcare Corporation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Notes to Consolidated Condensed Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The debt discount is amortized over the life of the note and recognized as interest expense. For the nine months ended September 30, 2021 and 2020, the Company amortized the debt discount of $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_ztFPUEc51iG7" title="Amortized of debt discount">0</span> and $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_zMid7AtEpupk" title="Amortized of debt discount">594,705</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zJAZNXPV2Cv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, the Company had the following activity in the derivative liability account:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BD_z6jGZHtFKS11" style="display: none">Schedule of Derivative Liability</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Notes</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Derivative liability at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zmg7CQMkUlg5" style="width: 18%; text-align: right" title="Derivative liability, beginning balance">3,925,106</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Change in fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zT2ATmD084c" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in fair value">(729,654</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Derivative liability at September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zf738JTi4TV6" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">3,195,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zkWkmh5IYEr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zVaOIqB3MpO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B1_zJWEiKLfZZwe" style="display: none">Schedule of Assumptions Used Black Scholes Valuation of Derivative</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Stock price at valuation date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_zmqZKPYHEpP6" title="Stock price at valuation date">.0005</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSHDaIiegtei" title="Derivative liability, fair value measurement input, percentage">.07</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock volatility factor</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zx0XM00ix8Ea" title="Derivative liability, fair value measurement input, percentage">409.80</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Years to Maturity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeTermOfContract_dtY_c20210101__20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_zA1YkBJI6Fqk" title="Derivative liability, term">.08</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dpn_uPure_c20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdUDv8wW91Q8" title="Derivative liability, fair value measurement input, percentage">None</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zINJKXrPh4W9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 0 594705 <p id="xdx_89C_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zJAZNXPV2Cv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, the Company had the following activity in the derivative liability account:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BD_z6jGZHtFKS11" style="display: none">Schedule of Derivative Liability</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Notes</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Derivative liability at December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zmg7CQMkUlg5" style="width: 18%; text-align: right" title="Derivative liability, beginning balance">3,925,106</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Change in fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_pp0p0_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zT2ATmD084c" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in fair value">(729,654</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Derivative liability at September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__custom--NotesMember_zf738JTi4TV6" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">3,195,452</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3925106 -729654 3195452 <p id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zVaOIqB3MpO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B1_zJWEiKLfZZwe" style="display: none">Schedule of Assumptions Used Black Scholes Valuation of Derivative</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Stock price at valuation date</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_zmqZKPYHEpP6" title="Stock price at valuation date">.0005</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dp_uPure_c20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSHDaIiegtei" title="Derivative liability, fair value measurement input, percentage">.07</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock volatility factor</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zx0XM00ix8Ea" title="Derivative liability, fair value measurement input, percentage">409.80</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Years to Maturity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeTermOfContract_dtY_c20210101__20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember_zA1YkBJI6Fqk" title="Derivative liability, term">.08</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dpn_uPure_c20210930__us-gaap--AwardTypeAxis__custom--DerivativeLiabilityMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdUDv8wW91Q8" title="Derivative liability, fair value measurement input, percentage">None</span></span></td><td style="text-align: left"> </td></tr> </table> 0.0005 0.0007 4.0980 P0Y29D 0 <p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zGuITtIGP7B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 8. <span id="xdx_829_zrnc7tOm2nWd">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">From October 1 until the filing of this report, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20211001__20211002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zcktWDZuvSC8" title="Shares issued during period for services, shares">800,000,000</span> shares of common stock for conversion of Series E Convertible Preferred shares.</span></p> 800000000 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
 9 Months Ended
Sep. 30, 2021
Nov. 09, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 000-55203  
Entity Registrant Name eWELLNESS HEALTHCARE CORPORATION  
Entity Central Index Key 0001550020  
Entity Tax Identification Number 90-1073143  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 1126 S Federal Hwy #464  
Entity Address, City or Town Fort Lauderdale  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33316  
City Area Code (855)  
Local Phone Number 470-1700  
Title of 12(b) Security Common shares  
Trading Symbol EWLL  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   18,507,683,628
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Condensed Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
CURRENT ASSETS    
Cash $ 1,620 $ 1,109
Prepaid expenses 3,235
Total current assets 1,620 4,344
Property & equipment, net 2,720 3,788
TOTAL ASSETS 4,340 8,132
CURRENT LIABILITIES    
Accounts payable and accrued expenses 1,171,669 892,164
Accrued expenses - related party 134,247 292,762
Accrued compensation 200,000 200,000
Convertible debt, net of discount 1,354,882 1,354,882
Derivative liability 3,195,452 3,925,106
Total current liabilities 6,056,250 6,664,914
Total Liabilities 6,056,250 6,664,914
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT    
Common stock, authorized 20,000,000,000 shares, $.001 par value, 17,707,683,627 and 16,862,481,961  issued and outstanding, respectively 17,707,684 16,862,482
Subscription receivable (68,338)
Shares to be issued 263
Additional paid in capital 18,003,412 16,097,866
Accumulated deficit (41,695,632) (39,618,090)
Total Stockholders’ Deficit (6,051,910) (6,656,782)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 4,340 8,132
Series A Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock value 697 697
Series C Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock value 92
Series D Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock value 20
Series E Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock value $ 155
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Common stock, shares authorized 20,000,000,000 20,000,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares issued 17,707,683,627 16,862,481,961
Common stock, shares outstanding 17,707,683,627 16,862,481,961
Series A Preferred Stock [Member]    
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 696,667 696,667
Preferred stock, shares outstanding 696,667 696,667
Series C Preferred Stock [Member]    
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares issued 920,000 0
Preferred stock, shares outstanding 920,000 0
Series D Preferred Stock [Member]    
Preferred stock, shares authorized 200,000 200,000
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares issued 200,000 0
Preferred stock, shares outstanding 200,000 0
Series E Preferred Stock [Member]    
Preferred stock, shares authorized 2,500,000 2,500,000
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares issued 1,545,680 0
Preferred stock, shares outstanding 1,545,680 0
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
REVENUE $ 125,274 $ 263,429
OPERATING EXPENSES        
Executive compensation 102,000 260,000 476,000
General and administrative 36,434 54,465 247,288 489,708
Professional fees 1,325,551 94,867 2,106,355 945,448
Total Operating Expenses 1,361,985 251,332 2,613,643 1,911,156
Loss from Operations (1,361,985) (126,058) (2,613,643) (1,647,727)
OTHER INCOME (EXPENSE)        
Interest income 1
Gain (loss) on derivative liability (1,761,669) 1,465,693 729,654 (2,734,266)
Loss on disposal of asset (3,866)
Interest expense (65,115) (112,837) (193,553) (876,870)
Net Income (Loss) before Income Taxes (3,188,769) 1,226,798 (2,077,542) (5,262,728)
Income tax expense
Net Income (Loss) $ (3,188,769) $ 1,226,798 $ (2,077,542) $ (5,262,728)
Basic and diluted (loss) per common share $ (0.00) $ 0.00 $ (0.00) $ (0.00)
Weighted average shares outstanding 17,707,683,627 9,749,989,477 17,279,563,597 5,049,047,707
Weighted average diluted shares outstanding 25,991,582,032 32,382,204,327 25,563,462,002 27,681,262,557
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Reconciliation of Stockholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Series E Preferred Stock [Member]
Common Stock [Member]
Subscription Receivable [Member]
Shares to be Issued [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 250 $ 12,752 $ 150 $ 23,942,830 $ (30,862,019) $ (6,906,037)
Balance, shares at Dec. 31, 2019 250,000 12,752,084          
Contributed services 162,000 162,000
Shares issued to officers, directors and consultants $ 282 844,718 845,000
Shares issued to officers, directors and consultants, shares 281,667                  
Shares issued for debt conversion $ 13,761,882 (12,161,555) 1,600,327
Shares issued for debt conversion, shares         13,761,881,370          
Shares issued for services $ 668 28 957 1,653
Shares issued for services, shares         668,332          
Derivative liability $ 4,506,628 $ 4,506,628
Shares issued for rounding - 50:1 split 48     (48)
Shares issued for rounding - 50:1 split, shares         47,876          
Net profit (loss) $ (5,262,728) $ (5,262,728)
Ending balance, value at Sep. 30, 2020 $ 532 $ 13,775,350 178 17,295,530 (36,124,747) (5,053,157)
Balance, shares at Sep. 30, 2020 531,667 13,775,349,662          
Beginning balance, value at Jun. 30, 2020 $ 477 $ 7,851,725 76 21,409,876 (37,351,545) (8,089,391)
Balance, shares at Jun. 30, 2020 476,667 7,851,724,496          
Contributed services 54,000 54,000
Shares issued to officers, directors and consultants $ 55 164,945 165,000
Shares issued to officers, directors and consultants, shares 55,000                  
Shares issued for debt conversion $ 5,923,625 (5,479,659) 443,966
Shares issued for debt conversion, shares         5,923,625,166          
Shares issued for services 102 102
Shares issued for services, shares                  
Derivative liability 1,146,368 1,146,368
Net profit (loss)                 1,226,798 1,226,798
Ending balance, value at Sep. 30, 2020 $ 532 $ 13,775,350 178 17,295,530 (36,124,747) (5,053,157)
Balance, shares at Sep. 30, 2020 531,667 13,775,349,662          
Beginning balance, value at Dec. 31, 2020 $ 697 $ 16,862,482 263 16,097,866 (39,618,090) (6,656,782)
Balance, shares at Dec. 31, 2020 696,667 16,862,481,961          
Shares issued to officers, directors and consultants $ 92 $ 20 $ 128 2,399,760 2,400,000
Shares issued to officers, directors and consultants, shares   920,000 200,000 1,280,000            
Shares issued for cash $ 35 (68,338) 349,965 281,662
Shares issued for cash, shares       350,000            
Shares issued for preferred share conversions $ (8) $ 843,200 (843,192)
Shares issued for preferred share conversions, shares       (84,320) 843,200,000          
Shares issued for services $ 2,002 (263) (987) 752
Shares issued for services, shares         2,001,666          
Net profit (loss) (2,077,542) (2,077,542)
Ending balance, value at Sep. 30, 2021 $ 697 $ 92 $ 20 $ 155 $ 17,707,684 (68,338) 18,003,412 (41,695,632) (6,051,910)
Balance, shares at Sep. 30, 2021 696,667 920,000 200,000 1,545,680 17,707,683,627          
Beginning balance, value at Jun. 30, 2021 $ 697 $ 92 $ 20 $ 27 $ 17,707,684 (94,975) 16,723,540 (38,506,864) (4,169,779)
Balance, shares at Jun. 30, 2021 696,667 920,000 200,000 265,680 17,707,683,627          
Shares issued to officers, directors and consultants $ 128 1,279,872 1,280,000
Shares issued to officers, directors and consultants, shares       1,280,000            
Shares issued for cash 26,637 26,637
Shares issued for cash, shares                  
Shares issued for preferred share conversions
Shares issued for preferred share conversions, shares                  
Shares issued for services  
Shares issued for services, shares                  
Net profit (loss) (3,188,769) (3,188,769)
Ending balance, value at Sep. 30, 2021 $ 697 $ 92 $ 20 $ 155 $ 17,707,684 $ (68,338) $ 18,003,412 $ (41,695,632) $ (6,051,910)
Balance, shares at Sep. 30, 2021 696,667 920,000 200,000 1,545,680 17,707,683,627          
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical)
 9 Months Ended
Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]  
Stock split, description 50:1 split
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Condensed Statement of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities    
Net income (loss) $ (2,077,542) $ (5,262,728)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 1,069 5,272
Contributed services 162,000
Shares issued to officers, directors and consultants 1,120,000 376,750
Shares issued for consulting services 1,280,752 1,653
Shares issued for financing costs 95,933
Amortization of debt discount and prepaids 771,793
(Gain) loss on derivative liability (729,654) 2,734,266
Loss on disposal of asset 3,866
Changes in operating assets and liabilities    
Prepaid expense 3,235 (19,707)
Accounts receivable (192,495)
Accounts payable and accrued expenses 279,504 638,533
Accounts payable - related party 196,460
Accrued expenses - related party (158,515) 25,489
Accrued compensation 182,887
Net cash used in operating activities (281,151) (280,028)
Cash flows from financing activities    
Proceeds from issuance of convertible debt 52,800
Original issue discount and debt issuance costs (7,800)
Proceeds from issuance of preferred series E 281,662
Net cash provided by financing activities 281,662 45,000
Net increase (decrease) in cash 511 (235,028)
Cash, beginning of period 1,109 240,722
Cash, end of period 1,620 5,694
Cash paid for:    
Taxes
Interest Expense
Non cash items:    
Shares issued for debt conversion $ 1,600,327
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
The Company
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company

Note 1. The Company

 

The Company and Nature of Business

 

eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. The Company has generated minimal revenues to date.

 

eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15% ownership in Bistromatics. This agreement eliminated all past due professional fees of $748,832. The transfer of rights was completed on December 31, 2020.

 

During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company has engaged in negotiations with a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”), for a potential business combination. In connection with such negotiations, the Company’s Board of Directors on March 8, 2021, approved the organization of EWLL Acquisition Corp. under the laws of Nevada as a new wholly owned subsidiary of the Company (“EWLL Acquisition”). The purpose of the formation of EWLL Acquisition was in contemplation of its merger with and into AMHP which would be the surviving entity and become a wholly owned subsidiary of the Company.

 

Pursuant to the Company’s intentions referenced above, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition and AMHP pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company, subject to filing of Articles of Merger with the State of Nevada. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist.

 

On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $0.001 per share to $0.0001 per share (“Par Value Change”); and (iii) implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. Following the filing of this Form 10Q, the application to FINRA will be filed for approval of these actions.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 

Going Concern

 

For the nine months ended September 30, 2021, the Company had no revenue. The Company has an accumulated loss of $41,695,632 and a working capital deficit of $6,054,630. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Fair Value of Financial Instruments

 

As of September 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,195,452   $-   $-   $3,195,452 
Total Liabilities measured at fair value  $3,195,452   $-   $-   $3,195,452 

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,925,106   $-   $-   $3,925,106 
Total Liabilities measured at fair value  $3,925,106   $-   $-   $3,925,106 

 

Revenue Recognition

 

The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed.

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions
 9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

Note 3. Related Party Transactions

 

Throughout the nine months ended September 30, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of September 30, 2021 and December 31, 2020 were $34,247 and $11,655, respectively. There were no expenses due to the board members, but the Company has accrued directors’ fees of $221,107 and $216,107 as of September 30, 2021 and December 31, 2020, respectively. Because the Company is not yet profitable the officers have agreed to defer compensation. The Company had accrued executive compensation of $200,000 and $200,000 as of September 30, 2021 and December 31, 2020, respectively.

 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Notes Payable
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Convertible Notes Payable

Note 4. Convertible Notes Payable

 

During the nine months ended September 30, 2021, there were no new convertible notes executed. During the nine months ended September 30, 2021, the Company accrued interest payable of $193,552 on previously executed convertible notes payable.

 

Year Ended December 31, 2020

 

In March 2020, the Company executed a 12% Convertible Promissory Note payable to an institutional investor in the principal amount of $52,800. The note, which is due on January 15, 2021, has an original issue discount of $4,800 and transaction costs of $3,000. After 180 days, the convertible note converts into common stock of the Company at a conversion price that shall be equal to 70% of the average of the two lowest per share trading prices for the ten (10) trading days prior to the conversion date. As of December 31, 2020, this note was fully converted and during the year ended December 31, 2020 the Company accrued interest of $2,880.

 

During the year ended December 31, 2020, the Company accrued interest of $330,871 for the 2019 convertible notes that were still outstanding throughout the year.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Transactions
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Equity Transactions

Note 5. Equity Transactions

 

Preferred Stock

 

The total number of shares of Series A Preferred Stock which the Company shall have authority to issue is 20,000,000 shares with a par value of $0.001 per share. During the year ended December 31, 2019, the Company authorized the issuance of 1,000,000 shares of preferred stock to officers, directors and consultants as deferred compensation and/or expense. The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance. The deferred compensation value of the shares will vest monthly at 1/24th of the calculated value of $3,000,000 and requisite expense or reduction of accrued compensation and/or accrued directors fees will be recorded. At the recording of the requisite vested share value, the corresponding number of preferred shares will be recorded as being issued. On May 22, 2020, two independent directors resigned and three officers/directors/consultant resigned. Therefore, the vesting of their preferred shares ceased on those dates per the authorization documents. As part of the Settlement and Compromise agreements signed by current officers, director and consultant on February 26, 2021, with effective date October 1, 2020, the shares issued became fully vested at the year ended December 31, 2020.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock. The Board authorized that the Company shall have the authority to issue 1,000,000 shares with a par value of $.0001 per share to be issued to persons designated by the Board. The Series C Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series C Preferred Stock.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights Limitations of Series D Preferred Stock. The Board authorized that the Company shall have the authority to issue 200,000 shares with a par value of $.0001 per share to be issued to persons designated by the Board. The Series D Preferred Stock has no stated maturity and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Holder decides to convert the shares of Series D Preferred Stock.

 

In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock. The Board authorized that the Company shall have authority to issue 2,500,000 shares with a par value of $.0001 per share. The Board of Directors may determine to : (i) issue a number of Series Preferred in a private placement at an offering price of $1.00 per share; (ii) issue the Series E Preferred in consideration for the cancellation of shares of the Company’s Series A Preferred held by the Corporation’s officers, directors and key personnel based on terms and conditions that the Board of Directors may determine; and (iii) issue the shares of Series E Preferred for such other purposes as the Board of Directors may determine.

 

The Series C, Series D and Series E Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

On May 4, 2021, the Board of Directors issued 350,000 shares of Series E Convertible Preferred Stock for the subscription agreements dated March 1, 2021 at the value of $1.00 per share. Since the full payment of $350,000 had not been received at the period ended September 30, 2021, there is a subscription receivable for $68,338.

 

On May 12, 2021, the Board of Directors authorized the issuance of 200,000 shares of Series D Voting Preferred Stock with a value of $200,000.

 

On May 20, 2021, the Board of Directors authorized the issuance of 920,000 shares of Series C Convertible Preferred Stock with a value of $920,000.

 

On July 1, 2021, the Board of Directors authorized the issuance of 1,280,000 shares of Series E Convertible Preferred Stock with a value of $1,280,000. These shares were issued on July 14, 2021.

 

Common Stock

 

On February 12, 2020, FINRA approved a 1:50 reverse split of the Company’s common stock. As noted throughout this document, all common shares are stated as if the 1:50 reverse split had been completed as of the beginning of the year ended December 31, 2020. Following the approval, the Company’s stock began trading under the symbol “EWLLD”. Due to rounding issues for the reverse split, the Company issued 47,876 additional shares of common stock.

 

On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million (1,900,000,000) shares of Common Stock to twenty billion (20,000,000,000) shares of Common Stock.

 

Nine Months Ended September 30, 2021

 

During the nine months ended September 30, 2021, the Company issued 2,001,666 shares of common stock for consultant services valued at $752.

 

During the nine months ended September 30, 2021, the Company issued 843,200,000 shares of common stock for conversion of 84,320 shares of preferred series E shares.

 

Nine Months Ended September 30, 2020

 

In January 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 shares of common stock monthly. The Company issued 80,000 shares of common stock with a value of $126. The Company needs to issue an additional 100,000 shares of common stock with a value of $20. In addition, the Company is to also pay the advisor a monthly fee of $2,500.

 

During the nine months ended September 30, 2020, the Company issued a total of 13,761,881,370 shares of common stock per debt conversion of various convertible notes. The total of the debt conversion was for $1,371,723 of principal, $132,671 of accrued interest and $95,933 of financing costs.

 

During the nine months ended September 30, 2020, the Company issued 668,332 shares of common stock for consultant services valued at $1,653 which includes the advisory services agreement discussed above.

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

Stock Options

 

The following is a summary of the status of all Company’s stock options as of September 30, 2021 and changes during the nine months ended on that date:

 

       Weighted         
   Number
of Stock		   Average
Exercise		   Remaining   Intrinsic 
   Options   Price   Life (yrs)   Value 
Outstanding on December 31, 2020   27,000   $40.00    .14   $- 
Granted   -    -           
Exercised   -    -           
Cancelled   (27,000)   -           
Outstanding on September 30, 2021   -    -    -   $- 
Options exercisable on September 30, 2021   -   $-    -   $- 

 

Warrants

 

The following is a summary of the status of the Company’s warrants as of September 30, 2021 and changes during the nine months ended on that date:

 

       Weighted         
   Number of   Average
Exercise		   Remaining   Intrinsic 
   Warrants   Price   Life (yrs.)   Value 
Outstanding on December 31, 2020   26,015   $12.50    1.2   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (26,015)   -    -    - 
Outstanding on September 30, 2021   -   $-    -   $- 
Warrants exercisable on September 30, 2021   -   $-    -   $- 

 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments, Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingencies

Note 6. Commitments, Contingencies

 

The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. The Company believes that there are no current matters that would have a material effect on the Company’s financial position or results of operations.

 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Derivative Valuation
 9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Valuation

Note 7. Derivative Valuation

 

The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. Therefore, these have been characterized as derivative instruments. The Company records the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. The Company records the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings.

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

The debt discount is amortized over the life of the note and recognized as interest expense. For the nine months ended September 30, 2021 and 2020, the Company amortized the debt discount of $0 and $594,705, respectively.

 

During the nine months ended September 30, 2021, the Company had the following activity in the derivative liability account:

 

   Notes 
Derivative liability at December 31, 2020  $3,925,106 
Change in fair value   (729,654)
Derivative liability at September 30, 2021  $3,195,452 

 

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date  $.0005 
Risk free interest rate   .07%
Stock volatility factor   409.80%
Years to Maturity   .08 
Expected dividend yield   None 

 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
 9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 8. Subsequent Events

 

From October 1 until the filing of this report, the Company issued 800,000,000 shares of common stock for conversion of Series E Convertible Preferred shares.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements. Accordingly, they omit or condense notes and certain other information normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles. The accounting policies followed for quarterly financial reporting conform with the accounting policies disclosed in Note 2 to the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, all adjustments necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2021. The unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments.

 
Going Concern

Going Concern

 

For the nine months ended September 30, 2021, the Company had no revenue. The Company has an accumulated loss of $41,695,632 and a working capital deficit of $6,054,630. The Company’s ability to continue operations is dependent upon the Company’s ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations, of which there can be no guarantee. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

As of September 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,195,452   $-   $-   $3,195,452 
Total Liabilities measured at fair value  $3,195,452   $-   $-   $3,195,452 

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,925,106   $-   $-   $3,925,106 
Total Liabilities measured at fair value  $3,925,106   $-   $-   $3,925,106 

 
Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue per ASC 606. Revenue is recognized when the services have been completed.

 
Reclassifications

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Summary of Assets and Liabilities Fair Value on Recurring Basis

As of September 30, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,195,452   $-   $-   $3,195,452 
Total Liabilities measured at fair value  $3,195,452   $-   $-   $3,195,452 

 

 

eWellness Healthcare Corporation

Notes to Consolidated Condensed Financial Statements

September 30, 2021

(unaudited)

 

As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis.

 

   Total   Level 1   Level 2   Level 3 
Derivative Liability  $3,925,106   $-   $-   $3,925,106 
Total Liabilities measured at fair value  $3,925,106   $-   $-   $3,925,106 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Transactions (Tables)
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Summary of Stock Options Activity

The following is a summary of the status of all Company’s stock options as of September 30, 2021 and changes during the nine months ended on that date:

 

       Weighted         
   Number
of Stock		   Average
Exercise		   Remaining   Intrinsic 
   Options   Price   Life (yrs)   Value 
Outstanding on December 31, 2020   27,000   $40.00    .14   $- 
Granted   -    -           
Exercised   -    -           
Cancelled   (27,000)   -           
Outstanding on September 30, 2021   -    -    -   $- 
Options exercisable on September 30, 2021   -   $-    -   $- 
Summary of Warrants Activity

The following is a summary of the status of the Company’s warrants as of September 30, 2021 and changes during the nine months ended on that date:

 

       Weighted         
   Number of   Average
Exercise		   Remaining   Intrinsic 
   Warrants   Price   Life (yrs.)   Value 
Outstanding on December 31, 2020   26,015   $12.50    1.2   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Cancelled   (26,015)   -    -    - 
Outstanding on September 30, 2021   -   $-    -   $- 
Warrants exercisable on September 30, 2021   -   $-    -   $- 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Derivative Valuation (Tables)
 9 Months Ended
Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Liability

During the nine months ended September 30, 2021, the Company had the following activity in the derivative liability account:

 

   Notes 
Derivative liability at December 31, 2020  $3,925,106 
Change in fair value   (729,654)
Derivative liability at September 30, 2021  $3,195,452 
Schedule of Assumptions Used Black Scholes Valuation of Derivative

For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follows:

 

Stock price at valuation date  $.0005 
Risk free interest rate   .07%
Stock volatility factor   409.80%
Years to Maturity   .08 
Expected dividend yield   None 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.2
The Company (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 15, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Professional Fees   $ 1,325,551 $ 94,867 $ 2,106,355 $ 945,448
Services Agreement [Member] | Bistromatics Inc. [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Equity Method Investment, Ownership Percentage 15.00%        
Professional Fees $ 748,832        
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) - USD ($)
Sep. 30, 2021
Sep. 30, 2020
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liability $ 3,195,452 $ 3,925,106
Total Liabilities measured at fair value 3,195,452 3,925,106
Fair Value, Inputs, Level 1 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liability
Total Liabilities measured at fair value
Fair Value, Inputs, Level 2 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liability
Total Liabilities measured at fair value
Fair Value, Inputs, Level 3 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Derivative Liability 3,195,452 3,925,106
Total Liabilities measured at fair value $ 3,195,452 $ 3,925,106
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Accumulated loss $ 41,695,632 $ 39,618,090
Working capital deficit $ 6,054,630  
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Details Narrative) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]    
Accrued directors fees $ 221,107 $ 216,107
Accrued executive compensation 200,000 200,000
Officers and Directors [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]    
Amounts due to officers $ 34,247 $ 11,655
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Convertible Notes Payable (Details Narrative)
 1 Months Ended
Mar. 31, 2020
USD ($)
Trading
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Convertible Notes Payable [Member]      
Short-term Debt [Line Items]      
Accrued interest   $ 193,552  
12% Convertible Promissory Note [Member]      
Short-term Debt [Line Items]      
Accrued interest     $ 2,880
Debt interest stated rate 12.00%    
Debt face amount $ 52,800    
Debt maturity date Jan. 15, 2021    
Original issue discount $ 4,800    
Transaction costs $ 3,000    
Convertible debt percentage 70.00%    
Number of trading days | Trading 10    
2019 Convertible Notes [Member]      
Short-term Debt [Line Items]      
Accrued interest     $ 330,871
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Stock Options Activity (Details)
 9 Months Ended
Sep. 30, 2021
USD ($)
$ / shares
shares
Equity [Abstract]  
Number of Stock Options Outstanding, Beginning Balance | shares 27,000
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares $ 40.00
Remaining Life (yrs) Outstanding, Beginning Balance 1 month 20 days
Intrinsic Value Outstanding, Beginning Balance | $
Number of Stock Options Outstanding, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Number of Stock Options Outstanding, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Stock Options Outstanding, Cancelled | shares (27,000)
Weighted Average Exercise Price, Cancelled | $ / shares
Number of Stock Options Outstanding, Ending Balance | shares
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares
Remaining Life (yrs) Outstanding, Ending Balance
Intrinsic Value Outstanding, Ending Balance | $
Number of Stock Options exercisable, Ending Balance | shares
Weighted Average Exercise Price Options exercisable, Ending Balance | $ / shares
Remaining Life (yrs) Options exercisable, Ending Balance
Intrinsic Value Options exercisable, Ending Balance | $
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Warrants Activity (Details)
 9 Months Ended
Sep. 30, 2021
$ / shares
shares
Equity [Abstract]  
Number of Warrants, Outstanding, Beginning Balance | shares 26,015
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance $ 12.50
Remaining Life (yrs.) Warrants Outstanding, Beginning Balance 1 year 2 months 12 days
Intrinsic Value, Warrants Outstanding, Beginning Balance
Number of Warrants, Granted | shares
Weighted Average Exercise Price, Warrants Granted
Remaining Life (yrs.) Warrants Outstanding, Granted
Intrinsic Value, Warrants Outstanding, Granted
Number of Warrants, Exercised | shares
Remaining Life (yrs.) Warrants Outstanding, Exercised
Intrinsic Value, Warrants Outstanding, Exercised
Number of Warrants, Cancelled | shares (26,015)
Remaining Life (yrs.) Warrants Outstanding, Cancelled
Intrinsic Value, Warrants Outstanding, Cancelled
Number of Warrants, Outstanding, Ending Balance | shares
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance
Remaining Life (yrs.) Warrants Outstanding, Ending Balance
Intrinsic Value, Warrants Outstanding, Ending Balance
Number of Warrants, exercisable, Ending balance | shares
Weighted Average Exercise Price Exercisable, Ending Balance
Remaining Life (yrs.) Warrants Exercisable, Ending Balance
Intrinsic Value, Warrants Outstanding, Exercisable
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Transactions (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 04, 2021
Feb. 12, 2020
Jan. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2019
Jul. 01, 2021
May 20, 2021
May 12, 2021
Apr. 30, 2021
Dec. 31, 2020
Apr. 30, 2020
Feb. 14, 2020
Class of Stock [Line Items]                              
Deferred compensation       $ 3,000,000   $ 3,000,000                  
Preferred Stock, Voting Rights           The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time.                  
Stock issued during the period, value       26,637   $ 281,662                  
Subscription receivable       $ 68,338   $ 68,338                
Common stock, shares authorized       20,000,000,000   20,000,000,000             20,000,000,000    
Convertible Notes [Member]                              
Class of Stock [Line Items]                              
Shares issued for debt conversion, shares             13,761,881,370                
Principal amount         $ 1,371,723   $ 1,371,723                
Accrued interest         132,671   132,671                
Financing costs             95,933                
12- month Advisory Services Agreement [Member]                              
Class of Stock [Line Items]                              
Number of shares issued, new issues     80,000     100,000                  
Stock issued during the period, value     $ 126     $ 20                  
Monthly base fee         $ 2,500   $ 2,500                
12- month Advisory Services Agreement [Member] | Monthly [Member]                              
Class of Stock [Line Items]                              
Number of shares issued, new issues     20,000                        
Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Conversion of stock, description           The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance.                  
Conversion of Stock, Shares Converted           40                  
Common Stock [Member]                              
Class of Stock [Line Items]                              
Stock issued during the period, value                          
Common stock, shares authorized       20,000,000,000   20,000,000,000                 1,900,000,000
Shares issued for services       2,001,666 668,332                
Number of shares issued, new issues           843,200,000                  
Officers,Directors and Consultants [Member]                              
Class of Stock [Line Items]                              
Preferred stock shares authorized               1,000,000              
Board of Directors [Member] | Common Stock [Member]                              
Class of Stock [Line Items]                              
Number of shares issued, new issues               47,876              
Reverse stock split, description   1:50           1:50              
Consultant [Member]                              
Class of Stock [Line Items]                              
Shares issued for services           2,001,666 668,332                
Value for services           $ 752 $ 1,653                
Series A Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock par value       $ 0.001   $ 0.001             $ 0.001    
Preferred stock shares authorized       20,000,000   20,000,000             20,000,000    
Preferred stock value       $ 697   $ 697             $ 697    
Series A Preferred Stock [Member] | Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Stock issued during the period, value                          
Series C Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock par value       $ 0.0001   $ 0.0001             $ 0.0001    
Preferred stock shares authorized       1,000,000   1,000,000             1,000,000    
Preferred stock value       $ 92   $ 92                
Series C Preferred Stock [Member] | Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Stock issued during the period, value                          
Series C Preferred Stock [Member] | Board of Directors [Member]                              
Class of Stock [Line Items]                              
Preferred stock par value                       $ 0.0001      
Preferred stock shares authorized                       1,000,000      
Series D Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock par value       $ 0.0001   $ 0.0001             $ 0.0001    
Preferred stock shares authorized       200,000   200,000             200,000    
Preferred stock value       $ 20   $ 20                
Series D Preferred Stock [Member] | Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Stock issued during the period, value                          
Series D Preferred Stock [Member] | Board of Directors [Member]                              
Class of Stock [Line Items]                              
Preferred stock par value                       $ 0.0001      
Preferred stock shares authorized                           200,000  
Series E Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock par value       $ 0.0001   $ 0.0001             $ 0.0001    
Preferred stock shares authorized       2,500,000   2,500,000             2,500,000    
Preferred stock value       $ 155   $ 155                
Series E Preferred Stock [Member] | Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Number of shares issued, new issues         350,000                  
Stock issued during the period, value         $ 35                  
Number of shares issued, new issues         (84,320)                  
Series E Preferred Stock [Member] | Board of Directors [Member]                              
Class of Stock [Line Items]                              
Preferred stock par value                       0.0001      
Preferred stock shares authorized                           2,500,000  
Offering price per share                       $ 1.00      
Series E Convertible Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock shares authorized                 1,280,000            
Offering price per share $ 1.00                            
Number of shares issued, new issues 350,000                            
Stock issued during the period, value $ 350,000                            
Preferred stock value                 $ 1,280,000            
Shares issued date                 Jul. 14, 2021            
Shares issued for debt conversion, shares           84,320                  
Series D Voting Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock shares authorized                     200,000        
Preferred stock value                     $ 200,000        
Series C Convertible Preferred Stock [Member]                              
Class of Stock [Line Items]                              
Preferred stock shares authorized                   920,000          
Preferred stock value                   $ 920,000          
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Derivative Liability (Details) - Notes [Member]
 9 Months Ended
Sep. 30, 2021
USD ($)
Derivative Instruments, Gain (Loss) [Line Items]  
Derivative liability, beginning balance $ 3,925,106
Change in fair value (729,654)
Derivative liability, ending balance $ 3,195,452
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) - Derivative Liability [Member]
 9 Months Ended
Sep. 30, 2021
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock price at valuation date $ 0.0005
Derivative liability, term 29 days
Measurement Input, Risk Free Interest Rate [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Derivative liability, fair value measurement input, percentage 0.0007
Measurement Input, Price Volatility [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Derivative liability, fair value measurement input, percentage 4.0980
Measurement Input, Expected Dividend Rate [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Derivative liability, fair value measurement input, percentage 0
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Derivative Valuation (Details Narrative) - USD ($)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Amortized of debt discount $ 771,793
Derivative Liability [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Amortized of debt discount $ 0 $ 594,705
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details Narrative)
Oct. 02, 2021
shares
Subsequent Event [Member] | Series E Convertible Preferred Stock [Member]  
Subsequent Event [Line Items]  
Shares issued during period for services, shares 800,000,000
EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 158 263 1 false 34 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://ewellnesshealth.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Condensed Balance Sheets (Unaudited) Sheet http://ewellnesshealth.com/role/CondensedBalanceSheets Consolidated Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Condensed Statements of Operations (Unaudited) Sheet http://ewellnesshealth.com/role/CondensedStatementsOfOperations Consolidated Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) Sheet http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit Reconciliation of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical) Sheet http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficitParenthetical Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Condensed Statement of Cash Flows (Unaudited) Sheet http://ewellnesshealth.com/role/CondensedStatementOfCashFlows Consolidated Condensed Statement of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - The Company Sheet http://ewellnesshealth.com/role/Company The Company Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://ewellnesshealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Convertible Notes Payable Notes http://ewellnesshealth.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Equity Transactions Sheet http://ewellnesshealth.com/role/EquityTransactions Equity Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Commitments, Contingencies Sheet http://ewellnesshealth.com/role/CommitmentsContingencies Commitments, Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Derivative Valuation Sheet http://ewellnesshealth.com/role/DerivativeValuation Derivative Valuation Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://ewellnesshealth.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Equity Transactions (Tables) Sheet http://ewellnesshealth.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://ewellnesshealth.com/role/EquityTransactions 18 false false R19.htm 00000019 - Disclosure - Derivative Valuation (Tables) Sheet http://ewellnesshealth.com/role/DerivativeValuationTables Derivative Valuation (Tables) Tables http://ewellnesshealth.com/role/DerivativeValuation 19 false false R20.htm 00000020 - Disclosure - The Company (Details Narrative) Sheet http://ewellnesshealth.com/role/CompanyDetailsNarrative The Company (Details Narrative) Details http://ewellnesshealth.com/role/Company 20 false false R21.htm 00000021 - Disclosure - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) Sheet http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) Details 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://ewellnesshealth.com/role/RelatedPartyTransactions 23 false false R24.htm 00000024 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://ewellnesshealth.com/role/ConvertibleNotesPayable 24 false false R25.htm 00000025 - Disclosure - Summary of Stock Options Activity (Details) Sheet http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails Summary of Stock Options Activity (Details) Details 25 false false R26.htm 00000026 - Disclosure - Summary of Warrants Activity (Details) Sheet http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails Summary of Warrants Activity (Details) Details 26 false false R27.htm 00000027 - Disclosure - Equity Transactions (Details Narrative) Sheet http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative Equity Transactions (Details Narrative) Details http://ewellnesshealth.com/role/EquityTransactionsTables 27 false false R28.htm 00000028 - Disclosure - Schedule of Derivative Liability (Details) Sheet http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails Schedule of Derivative Liability (Details) Details 28 false false R29.htm 00000029 - Disclosure - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Sheet http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) Details 29 false false R30.htm 00000030 - Disclosure - Derivative Valuation (Details Narrative) Sheet http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative Derivative Valuation (Details Narrative) Details http://ewellnesshealth.com/role/DerivativeValuationTables 30 false false R31.htm 00000031 - Disclosure - Subsequent Events (Details Narrative) Sheet http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://ewellnesshealth.com/role/SubsequentEvents 31 false false All Reports Book All Reports form10-q.htm ewll-20210930.xsd ewll-20210930_cal.xml ewll-20210930_def.xml ewll-20210930_lab.xml ewll-20210930_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm form10-q_001.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 158, "dts": { "calculationLink": { "local": [ "ewll-20210930_cal.xml" ] }, "definitionLink": { "local": [ "ewll-20210930_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "ewll-20210930_lab.xml" ] }, "presentationLink": { "local": [ "ewll-20210930_pre.xml" ] }, "schema": { "local": [ "ewll-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 328, "entityCount": 1, "hidden": { "http://ewellnesshealth.com/20210930": 149, "http://fasb.org/us-gaap/2021-01-31": 141, "http://xbrl.sec.gov/dei/2021": 4, "total": 294 }, "keyCustom": 39, "keyStandard": 224, "memberCustom": 18, "memberStandard": 16, "nsprefix": "EWLL", "nsuri": "http://ewellnesshealth.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ewellnesshealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Related Party Transactions", "role": "http://ewellnesshealth.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Convertible Notes Payable", "role": "http://ewellnesshealth.com/role/ConvertibleNotesPayable", "shortName": "Convertible Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Equity Transactions", "role": "http://ewellnesshealth.com/role/EquityTransactions", "shortName": "Equity Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Commitments, Contingencies", "role": "http://ewellnesshealth.com/role/CommitmentsContingencies", "shortName": "Commitments, Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Derivative Valuation", "role": "http://ewellnesshealth.com/role/DerivativeValuation", "shortName": "Derivative Valuation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Subsequent Events", "role": "http://ewellnesshealth.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Equity Transactions (Tables)", "role": "http://ewellnesshealth.com/role/EquityTransactionsTables", "shortName": "Equity Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Derivative Valuation (Tables)", "role": "http://ewellnesshealth.com/role/DerivativeValuationTables", "shortName": "Derivative Valuation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Condensed Balance Sheets (Unaudited)", "role": "http://ewellnesshealth.com/role/CondensedBalanceSheets", "shortName": "Consolidated Condensed Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - The Company (Details Narrative)", "role": "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "shortName": "The Company (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-09-15_custom_ServicesAgreementMember_custom_BistromaticsIncMember", "decimals": "INF", "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Summary of Assets and Liabilities Fair Value on Recurring Basis (Details)", "role": "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails", "shortName": "Summary of Assets and Liabilities Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "EWLL:GoingConcernPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "EWLL:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Convertible Notes Payable (Details Narrative)", "role": "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "Convertible Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_ConvertibleNotesPayableMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Summary of Stock Options Activity (Details)", "role": "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails", "shortName": "Summary of Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Summary of Warrants Activity (Details)", "role": "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails", "shortName": "Summary of Warrants Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Equity Transactions (Details Narrative)", "role": "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "shortName": "Equity Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "lang": "en-US", "name": "us-gaap:PreferredStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_custom_NotesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Schedule of Derivative Liability (Details)", "role": "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails", "shortName": "Schedule of Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_custom_NotesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_custom_DerivativeLiabilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details)", "role": "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails", "shortName": "Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_custom_DerivativeLiabilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical)", "role": "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "shortName": "Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Derivative Valuation (Details Narrative)", "role": "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "shortName": "Derivative Valuation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-09-30_custom_DerivativeLiabilityMember", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-10-012021-10-02_us-gaap_SubsequentEventMember_custom_SeriesEConvertiblePreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-10-012021-10-02_us-gaap_SubsequentEventMember_custom_SeriesEConvertiblePreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Condensed Statements of Operations (Unaudited)", "role": "http://ewellnesshealth.com/role/CondensedStatementsOfOperations", "shortName": "Consolidated Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Reconciliation of Stockholders' Deficit (Unaudited)", "role": "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "shortName": "Reconciliation of Stockholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical)", "role": "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficitParenthetical", "shortName": "Reconciliation of Stockholders' Deficit (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Condensed Statement of Cash Flows (Unaudited)", "role": "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows", "shortName": "Consolidated Condensed Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - The Company", "role": "http://ewellnesshealth.com/role/Company", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 34, "tag": { "EWLL_AccruedLiabilitiesRelatedPartiesCurrent": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued liabilities related parties current.", "label": "Accrued expenses - related party" } } }, "localname": "AccruedLiabilitiesRelatedPartiesCurrent", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "EWLL_AdjustmentsToAdditionalPaidInCapitalContributedServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital contributed services.", "label": "Contributed services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalContributedServices", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_BistromaticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bistromatics Inc. [Member]", "label": "Bistromatics Inc. [Member]" } } }, "localname": "BistromaticsIncMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Board of Directors [Member]", "label": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_CashPaidAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Paid [Abstract]", "label": "Cash paid for:" } } }, "localname": "CashPaidAbstract", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "EWLL_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member]", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_ContributedServices": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contributed services.", "label": "ContributedServices", "verboseLabel": "Contributed services" } } }, "localname": "ContributedServices", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes [Member]", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_DerivativeLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative liability.", "label": "DerivativeLiability", "verboseLabel": "Derivative liability" } } }, "localname": "DerivativeLiability", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_DerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liability [Member]", "label": "Derivative Liability [Member]" } } }, "localname": "DerivativeLiabilityMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "EWLL_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going Concern [Policy Text Block]", "label": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "EWLL_IncreaseDecreaseInAccountsReceivableNet": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivableNet", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_IncreaseDecreaseInAccruedLiabilitiesRelatedParties": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued liabilities related parties.", "label": "IncreaseDecreaseInAccruedLiabilitiesRelatedParties", "verboseLabel": "Accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesRelatedParties", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_IncreaseDecreaseInPrepaidExpenseNet": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid expense" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseNet", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_MonthlyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Monthly [Member]", "label": "Monthly [Member]" } } }, "localname": "MonthlyMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes [Member]", "label": "Notes [Member]" } } }, "localname": "NotesMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "EWLL_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Officers and Directors [Member]", "label": "Officers and Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_OfficersDirectorsAndConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Officers,Directors and Consultants [Member]", "label": "Officers,Directors and Consultants [Member]" } } }, "localname": "OfficersDirectorsAndConsultantsMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Preferred Stock [Member]", "label": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_SeriesDVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Voting Preferred Stock [Member]", "label": "Series D Voting Preferred Stock [Member]" } } }, "localname": "SeriesDVotingPreferredStockMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_SeriesEConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E Convertible Preferred Stock [Member]", "label": "Series E Convertible Preferred Stock [Member]" } } }, "localname": "SeriesEConvertiblePreferredStockMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_ServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Services Agreement [Member]", "label": "Services Agreement [Member]" } } }, "localname": "ServicesAgreementMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Warrants, exercisable, Ending balance.", "label": "Number of Warrants, exercisable, Ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableNumber", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisdInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Exercised In Period Weighted Average Exercise Price.", "label": "Remaining Life (yrs.) Warrants Outstanding, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionExercisdInPeriodWeightedAverageExercisePrice", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Forfeited Or Expired In Period Weighted Average Exercise Price.", "label": "Remaining Life (yrs.) Warrants Outstanding, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionForfeitedInPeriodWeightedAverageExercisePrice", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrandInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Grand In Period Weighted Average Exercise Price.", "label": "Weighted Average Exercise Price, Warrants Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrandInPeriodWeightedAverageExercisePrice", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Exercisable Ending.", "label": "Weighted Average Exercise Price Exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingExercisableWeightedAverageNumberOfShare", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Outstanding Weighted Average Number Of Share.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare", "periodEndLabel": "Weighted Average Exercise Price, Warrants Outstanding, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageNumberOfShare", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intrinsic Value, Warrants Outstanding.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic", "periodEndLabel": "Intrinsic Value, Warrants Outstanding, Ending Balance", "periodStartLabel": "Intrinsic Value, Warrants Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantBeginningInPeriodGrantDateIntrinsic", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentWarrantCancelledInPeriodGrantDateIntrinsic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intrinsic Value, Warrants Outstanding, Cancelled", "label": "Intrinsic Value, Warrants Outstanding, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantCancelledInPeriodGrantDateIntrinsic", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisableInPeriodGrantDateIntrinsic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Warrants Exercisable", "label": "Intrinsic Value, Warrants Outstanding, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisableInPeriodGrantDateIntrinsic", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisedInPeriodGrantDateIntrinsic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intrinsic Value, Warrants Outstanding, Exercised", "label": "Intrinsic Value, Warrants Outstanding, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantExercisedInPeriodGrantDateIntrinsic", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_ShareBasedCompensationArrangementByShareBasedPaymentWarrantGrantedInPeriodGrantDateIntrinsic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intrinsic Value, Warrants Outstanding, Granted", "label": "Intrinsic Value, Warrants Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentWarrantGrantedInPeriodGrantDateIntrinsic", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs), Ending.", "label": "Remaining Life (yrs) Outstanding, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingEndingWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentWarrantsExercisableWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs), Exercisable Ending.", "label": "Remaining Life (yrs.) Warrants Exercisable, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentWarrantsExercisableWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingEndingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs), Ending.", "label": "Remaining Life (yrs.) Warrants Outstanding, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingEndingWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs), Beginning.", "label": "Remaining Life (yrs.) Warrants Outstanding, Beginning Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTermGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Life (yrs.) Warrants Outstanding, Granted", "label": "Remaining Life (yrs.) Warrants Outstanding, Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentWarrantsOutstandingWeightedAverageRemainingContractualTermGranted", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "EWLL_SharesIssuedForConsultingServices": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued for consulting services.", "label": "Shares issued for consulting services" } } }, "localname": "SharesIssuedForConsultingServices", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesIssuedForDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued for debt conversion.", "label": "SharesIssuedForDebtConversion", "verboseLabel": "Shares issued for debt conversion" } } }, "localname": "SharesIssuedForDebtConversion", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesIssuedForFinancingCosts": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued for financing costs.", "label": "Shares issued for financing costs" } } }, "localname": "SharesIssuedForFinancingCosts", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesIssuedForPreferredShareConversions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued for preferred share conversions", "label": "Shares issued for preferred share conversions" } } }, "localname": "SharesIssuedForPreferredShareConversions", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesIssuedForPreferredShareConversionsOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued for preferred share conversions of share", "label": "Shares issued for preferred share conversions, shares", "verboseLabel": "Number of shares issued, new issues" } } }, "localname": "SharesIssuedForPreferredShareConversionsOfShare", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "EWLL_SharesIssuedToOfficersDirectorsAndConsultants": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued to officers directors and consultants.", "label": "SharesIssuedToOfficersDirectorsAndConsultants", "verboseLabel": "Shares issued to officers, directors and consultants" } } }, "localname": "SharesIssuedToOfficersDirectorsAndConsultants", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesToBeIssued": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares to be issued.", "label": "Shares to be issued" } } }, "localname": "SharesToBeIssued", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "EWLL_SharesToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares to be Issued [Member]", "label": "Shares to be Issued [Member]" } } }, "localname": "SharesToBeIssuedMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "EWLL_StockIssuedDuringPeriodSharesDebtConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued for debt conversion, shares.", "label": "Shares issued for debt conversion, shares" } } }, "localname": "StockIssuedDuringPeriodSharesDebtConversion", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "EWLL_StockIssuedDuringPeriodSharesOfficersAndDirectors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares officers and directors", "label": "Shares issued to officers, directors and consultants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOfficersAndDirectors", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "EWLL_StockIssuedDuringPeriodValueDebtConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued for debt conversion.", "label": "Shares issued for debt conversion" } } }, "localname": "StockIssuedDuringPeriodValueDebtConversion", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_StockIssuedDuringPeriodValueIssuedForService": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued for services.", "label": "Shares issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForService", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_StockIssuedDuringPeriodValueOfficersAndDirectors": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued to officers, directors and cosultants.", "label": "Shares issued to officers, directors and consultants" } } }, "localname": "StockIssuedDuringPeriodValueOfficersAndDirectors", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "EWLL_StockIssuedDuringPeriodValueReverseStockSplits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value reverse stock splits.", "label": "Shares issued for rounding - 50:1 split" } } }, "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "EWLL_SubscriptionReceivable": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subscription receivable.", "label": "Subscription receivable", "negatedLabel": "Subscription receivable" } } }, "localname": "SubscriptionReceivable", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "EWLL_SubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Receivable [Member].", "label": "Subscription Receivable [Member]" } } }, "localname": "SubscriptionReceivableMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "EWLL_TwelveMonthAdvisoryServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "12- month Advisory Services Agreement [Member]", "label": "12- month Advisory Services Agreement [Member]" } } }, "localname": "TwelveMonthAdvisoryServicesAgreementMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_TwelvePercentConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "12% Convertible Promissory Note [Member]", "label": "12% Convertible Promissory Note [Member]" } } }, "localname": "TwelvePercentConvertiblePromissoryNoteMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_TwoThousandNineteenConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Convertible Notes [Member]", "label": "2019 Convertible Notes [Member]" } } }, "localname": "TwoThousandNineteenConvertibleNotesMember", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "EWLL_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://ewellnesshealth.com/20210930", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r370", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Series [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://ewellnesshealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r88", "r92", "r247" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r88", "r92", "r145", "r247", "r325" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r132", "r317" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r336", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued directors fees" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r267", "r322" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r80", "r81", "r82", "r264", "r265", "r266", "r289" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r51", "r61", "r183", "r309" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount and prepaids", "verboseLabel": "Amortized of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows", "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r75", "r118", "r121", "r127", "r135", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r274", "r276", "r300", "r320", "r322", "r332", "r343" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r38", "r75", "r135", "r147", "r148", "r149", "r151", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r274", "r276", "r300", "r320", "r322" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r250", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r23", "r63" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r57", "r63", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r57", "r301" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r72", "r75", "r95", "r96", "r97", "r99", "r101", "r103", "r104", "r105", "r135", "r147", "r152", "r153", "r154", "r158", "r159", "r195", "r196", "r200", "r204", "r300", "r376" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r144", "r337", "r347" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r141", "r142", "r143", "r146", "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments, Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CommitmentsContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r80", "r81", "r289" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r322" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, authorized 20,000,000,000 shares, $.001 par value, 17,707,683,627 and 16,862,481,961\u00a0\u00a0issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r65", "r66", "r67" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock, description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r65", "r66", "r67" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible debt, net of discount" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r12", "r333", "r342", "r357" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r65", "r67" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "verboseLabel": "Shares issued for debt conversion, shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r71", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r177", "r184", "r185", "r186", "r191" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Convertible Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r74", "r78", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r187", "r188", "r189", "r190", "r312", "r333", "r334", "r342" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Convertible debt percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Number of trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r160", "r187", "r188", "r310", "r312", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt face amount", "verboseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r31", "r161" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt interest stated rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r32", "r163", "r295" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r33", "r74", "r78", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r187", "r188", "r189", "r190", "r312" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r173", "r309", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Original issue discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r37", "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r24", "r173", "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Transaction costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r61", "r139" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Liability" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r281" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Gain (loss) on derivative liability", "negatedLabel": "(Gain) loss on derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows", "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r41", "r280", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r288", "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Valuation" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r279", "r280", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r39", "r40", "r41", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability [Default Label]", "periodEndLabel": "Derivative liability, ending balance", "periodStartLabel": "Derivative liability, beginning balance" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative liability, fair value measurement input, percentage" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative liability, term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r25", "r77", "r150", "r152", "r153", "r157", "r158", "r159", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Amounts due to officers" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted (loss) per common share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation", "verboseLabel": "Accrued executive compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r44", "r45", "r46", "r80", "r81", "r82", "r84", "r89", "r91", "r102", "r136", "r211", "r218", "r264", "r265", "r266", "r269", "r270", "r289", "r302", "r303", "r304", "r305", "r306", "r307", "r352", "r353", "r354", "r381" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of Assumptions Used Black Scholes Valuation of Derivative" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r175", "r187", "r188", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r246", "r293", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r175", "r235", "r236", "r241", "r246", "r293", "r327" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r175", "r187", "r188", "r235", "r236", "r241", "r246", "r293", "r328" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r175", "r187", "r188", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r246", "r293", "r329" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r175", "r187", "r188", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r246", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Total Liabilities measured at fair value" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.", "label": "Change in fair value" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r61" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Loss on disposal of asset", "negatedLabel": "Loss on disposal of asset" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows", "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r47", "r118", "r120", "r123", "r126", "r128", "r331", "r338", "r340", "r350" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net Income (Loss) before Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r90", "r91", "r117", "r268", "r271", "r272", "r351" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r60" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r60" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Accounts payable - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r60" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "verboseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r56", "r58", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Expense" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r8", "r9", "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r336", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28", "r75", "r122", "r135", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r275", "r276", "r277", "r300", "r320", "r321" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r75", "r135", "r300", "r322", "r335", "r345" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30", "r75", "r135", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r275", "r276", "r277", "r300", "r320", "r321", "r322" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_ManagementFeePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.", "label": "Monthly base fee" } } }, "localname": "ManagementFeePayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r106", "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "The Company" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/Company" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r57" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r57", "r59", "r62" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r42", "r43", "r46", "r48", "r62", "r75", "r83", "r85", "r86", "r87", "r88", "r90", "r91", "r98", "r118", "r120", "r123", "r126", "r128", "r135", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r156", "r158", "r159", "r290", "r300", "r339", "r349" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net profit (loss)", "totalLabel": "Net Income (Loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows", "http://ewellnesshealth.com/role/CondensedStatementsOfOperations", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non cash items:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r49" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Executive compensation" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r118", "r120", "r123", "r126", "r128" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r54" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Original issue discount and debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionDate": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Date when preferred stock can be converted into common shares, in YYYY-MM-DD format.", "label": "Shares issued date" } } }, "localname": "PreferredStockConvertibleConversionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r195" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r195" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r322" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r16", "r212" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r137", "r138" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r53" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r52" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from issuance of preferred series E" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r358", "r359" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees", "verboseLabel": "Professional Fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r140", "r322", "r341", "r346" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property & equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r314", "r315", "r316", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r218", "r267", "r322", "r344", "r355", "r356" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated loss" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r80", "r81", "r82", "r84", "r89", "r91", "r136", "r264", "r265", "r266", "r269", "r270", "r289", "r352", "r354" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r115", "r116", "r119", "r124", "r125", "r129", "r130", "r131", "r230", "r231", "r330" ], "calculation": { "http://ewellnesshealth.com/role/CondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r70", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r232" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r242", "r243", "r244", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfAssetsAndLiabilitiesFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Derivative Liability" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Summary of Assets and Liabilities Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r250", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r252", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Summary of Stock Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r35", "r72", "r103", "r104", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r204", "r209", "r212", "r213", "r214", "r215", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r220", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Summary of Warrants Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of Warrants, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedLabel": "Number of Warrants, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of Warrants, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r253", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Warrants, Outstanding, Ending Balance", "periodStartLabel": "Number of Warrants, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Number of Stock Options exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted Average Exercise Price Options exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Stock Options Outstanding, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Stock Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Intrinsic Value Outstanding, Ending Balance", "periodStartLabel": "Intrinsic Value Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r254", "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Stock Options Outstanding, Ending Balance", "periodStartLabel": "Number of Stock Options Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r249", "r251" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/DerivativeValuationDetailsNarrative", "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock price at valuation date" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ScheduleOfAssumptionsUsedBlackScholesValuationOfDerivativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Intrinsic Value Options exercisable, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Remaining Life (yrs) Options exercisable, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Remaining Life (yrs) Outstanding, Beginning Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Offering price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r69", "r79" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r72", "r75", "r95", "r96", "r97", "r99", "r101", "r103", "r104", "r105", "r135", "r147", "r152", "r153", "r154", "r158", "r159", "r195", "r196", "r200", "r204", "r211", "r300", "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r44", "r45", "r46", "r80", "r81", "r82", "r84", "r89", "r91", "r102", "r136", "r211", "r218", "r264", "r265", "r266", "r269", "r270", "r289", "r302", "r303", "r304", "r305", "r306", "r307", "r352", "r353", "r354", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r80", "r81", "r82", "r102", "r330" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/CondensedBalanceSheetsParenthetical", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued for services, shares", "terseLabel": "Shares issued during period for services, shares", "verboseLabel": "Shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit", "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r211", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued for cash, shares", "verboseLabel": "Number of shares issued, new issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Shares issued for rounding - 50:1 split, shares" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r211", "r218", "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Number of Stock Options Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Value for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r211", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Shares issued for cash", "verboseLabel": "Stock issued during the period, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r20", "r21", "r75", "r133", "r135", "r300", "r322" ], "calculation": { "http://ewellnesshealth.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets", "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r73", "r196", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r218", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Equity Transactions" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplit": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stock split, description" } } }, "localname": "StockholdersEquityNoteStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/ReconciliationOfStockholdersDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r308", "r324" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r308", "r324" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r308", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r308", "r324" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CompanyDetailsNarrative", "http://ewellnesshealth.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r107", "r108", "r109", "r110", "r111", "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r94", "r101" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average diluted shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r93", "r101" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://ewellnesshealth.com/role/CondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r362": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r363": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r364": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r365": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r366": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r367": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r368": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r369": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r371": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r372": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r373": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r374": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r375": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r376": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r377": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r378": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r379": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" } }, "version": "2.1" } ZIP 50 0001493152-21-027645-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-027645-xbrl.zip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